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Head and neck squamous cell carcinoma (HNSCC) is the 6
th
 most prevalent 
cancer worldwide, and more than 12,000 deaths from this disease are anticipated in 2015 
in the U.S. alone. The advent of the “Big Data” era for biomedicine, through the 
widespread use of genomic, transcriptomic, and other –omic data acquisition 
technologies, has enabled deeper exploration of the molecular-level mechanisms behind 
HNSCC development and progression. This knowledge in turn can lead to earlier 
diagnosis and better treatment strategies, resulting overall in better patient outcomes. 
However, the volume and complexity of –omic data present a major obstacle to fully 
realizing its potential to accelerate and enable basic and translational research for 
HNSCC.  
The goal of this Ph.D. dissertation is to address several key technical challenges 
related to harnessing –omic data for clinical HNSCC research. These are (1) the lack of 
knowledge-driven modeling tools and systems for discovering biomarkers at the protein 
and metabolite levels; (2) the lack of effective strategies for integrating heterogeneous 
types of –omic data for prediction; and (3) the lack of systems-level representations of 
biomarker knowledge for effectively predicting responses to bioactive agents. This 
dissertation addresses these challenges through three specific aims:  
1. Knowledge-driven  Data Mining: To develop modeling tools to mine  –omic  
datasets in HNSCC for biomarker discovery by harnessing existing knowledge 
2. Integrated –Omic Modeling: To develop supervised learning models for 
predicting HNSCC  progression through integration of –omic datasets 
xviii 
 
3. System Modeling: To develop dynamic system models for predicting response to 
combinations of multi-target agents against HNSCC 
The research in this dissertation was completed in collaboration with the Winship 
Cancer Institute and Georgia Institute of Technology. The models and tools developed 
have been systematically evaluated and validated using a variety of –omic data types. 
These results and associated case studies demonstrate the contribution of this work to and 

















1.1 Head and Neck Squamous Cell Carcinoma (HNSCC) 
Head and neck cancer arises in the upper aerodigestive tract, at regions including 
the oral cavity, oropharynx, larynx, hypopharynx and tongue, as shown in Figure 1.1. As 
the vast majority (more than 95%) of head and neck cancers are squamous cell 
carcinomas [1], hereafter in this dissertation the disease will be referred to as head and 
neck squamous cell carcinoma (HNSCC).  
 
Figure 1.1: Disease subsites for HNSCC. Figure from National Cancer Institute: 
http://www.cancer.gov/cancertopics/factsheet/Sites-Types/head-and-neck 
 
1.1.1. Statistics and Epidemiology 
HNSCC is the 6
th
 most prevalent cancer globally, with more than 600,000 new 
cases expected annually [1-4]. In the U.S. in particular, it represents 3% of all cancers, 
and in 2015 approximately 60,000 new cases and more than 12,000 deaths are expected.  
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Historically, HNSCC has been associated with alcohol and tobacco usage, and 
particularly by their use in combination [1, 5]. There is also a high prevalence of the 
disease in East and Southeast Asia, associated with the popularity of betel (areca) nut 
chewing [6, 7]. Overall, the disease is most prevalent among males over the age of 60. 
However, there is a growing subpopulation of HNSCC cases associated with human 
papillomavirus (HPV) infection. These patients tend to be younger, lack a history of 
alcohol and tobacco use, and predominantly experience cancer of the oropharynx.  
1.1.2. Current Approaches for Treatment and Prevention 
HNSCC treatment options include surgery, radiation, chemotherapy, or 
combinations of these treatments; specific treatment protocols vary based on disease sub-
site and the stage at which the cancer presents [8]. Many patients with locally advanced 
(stage III/IV) disease respond favorably to treatments, and reach the so-called No 
Evidence of Disease (NED) status [9-13]. However, NED patients often later experience 
recurrence, secondary primary tumor (SPT) development, or metastatic disease. These 
factors give rise to the poor 5-year survival percentages (near 50%) observed for many 
HNSCC subsites [14].   
1.2. The Role of Big Data: Opportunities and Challenges 
The sequencing of the human genome in the previous decade heralded the era of 
“Big Data” in biomedicine. The concept of Big Data refers not only to the size of datasets 
being generated, but also to the complexity, quality, and utility of the measured features 
and to the speed of overall data acquisition. A common shorthand for these characteristics 




Figure 1.2: Analysis pipeline for Big Data in biomedicine 
 
establishment of the Big Data to Knowledge (BD2K) initiative by the National Institutes 
of Health emphasizes the importance of this direction of research to multiple diseases, 
including cancers. The fundamental goal of Big Data analysis is to transform raw data, 
which may be too voluminous and complex for human interpretation, into organized, 
high-quality information and then into easily understandable knowledge. This is in turn 
used for decision-making and concrete actions. Figure 1.2 describes this pipeline.  
In biomedicine, this pipeline is embodied by the identification of putative 
biomarkers that can be validated and then applied in clinical practice. Such biomarkers 
are individual genes, proteins, or other types of measurable characteristics which are 
associated with the disease state. There are two main reasons why biomarker research is 
important [17-19]. First, biomarkers may be harnessed for clinically relevant goals such 
as early detection, diagnosis, or patient stratification. Second, identified molecules may 
themselves be druggable targets, or they may interact with such targets, and therefore are 
of interest in pharmaceutical research.  
One of the main sources of Big Data in biomedicine are the so-called ‘-omic’ 
technologies, which are capable of measuring completely, or to a large coverage extent, 
the genome, epigenome (epigenetic modifications), transcriptome (mRNA transcripts), 
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proteome (expressed as well as functionally active proteins), metabolome (metabolites, 
including lipids), and other bio-molecular feature spaces. The availability of these large-
scale, high-resolution data has helped to identify molecular expression patterns 
underlying many diseases, including HNSCC [20-22]. However, harnessing the potential 
of Big Data for HNSCC is far from complete. Here, I identify three major challenges 
related to applying –omic data for better understanding of HNSCC characteristics and for 
translating them into therapeutic strategies.  
1.2.1. Genomics and Downstream –Omics: Knowledge-driven Mining for 
Transcriptomics, Proteomics, and Metabolomics 
Cancer is a genetic disease in the sense that the transformation of normal cells to 
cancer cells is driven by alterations to the genome [23-27]. Great strides have been made 
in uncovering genomic changes associated with many types of cancers, including 
HNSCC. In particular, large-scale initiatives by The Cancer Genome Atlas have 
systematically explored the patterns in mutations, copy number variations, and epigenetic 
effects associated with HNSCC [28-30]. Validated oncogenes, such as PIK3CA and 
CCND1, and tumor suppressors, such as TP53 and PTEN, have focused attention on key 
biological pathways and processes that contribute to the development and progression of 
HNSCC. The most recent such analysis by TCGA also delineated four different sub-types 
of HNSCC [30].   
However, identifying alterations at the genomic level is insufficient to fully 
characterize the disease state. Downstream effects of the altered genome propagate 
through and modify the expression of genes, proteins, and metabolites. The ongoing 




Figure 1.3: Comparison of the current number of PubMed hits for alternative –omics 
technologies in combination with head and neck cancer 
 
provides powerful tools for data acquisition at these –omic levels. However, compared to 
progress in genomics, HNSCC research in proteomics – and especially in metabolomics – 
remains at an early stage. For example, Figure 1.3 compares publication counts in 
PubMed for these areas. One of the reasons is the inherent nature of the data: while 
genomic and transcriptomic data are completely described by nucleic acid sequences, 
amino acids describe only protein primary structure. Protein function and activity are 
determined by higher order structures and a complex network of regulatory interactions. 
Metabolites also exhibit great structural diversity, and are not encoded in the genome at 
all. In addition to this, high variation in abundance levels makes measurement and 
identification – and hence data interpretation – challenging [31]. Another critical reason 
is the lag in developing appropriate computational tools [32]. However, recent studies 
have underscored the importance of proteomics and metabolomics in understanding 


























Figure 1.4: Comparison of the 5-year survival rates (point estimates) for early (solid 
lines) and locally advanced (dashed lines) HNSCC of the tonsil, tongue, and oral cavity, 
between 1982 and 2006. Data from [14]. 
 
mathematical models and tools for accelerating the identification of putative HNSCC 
biomarkers, particularly for proteomic and metabolomic data. And fundamentally, it is of 
interest to develop knowledge-driven models and tools, which can harness existing 
biological and biomarker knowledge to facilitate and accelerate data mining.  
1.2.2. Integrated –Omics for Predicting Disease Progression 
For most HNSCC subsites, there is a large difference in expected outcomes 
depending on the stage at which the disease is detected [14, 37]. Figure 1.4 shows trends 
for three subsites. Therefore, understanding the molecular-level changes that accompany 
disease development and progression could result in biomarkers for early diagnosis and 
in potential therapeutic targets. Recent modeling studies have investigated the differences 
between pre-malignant lesions and oral cancer using transcriptomic data [38, 39], and 
several transcriptomic, proteomic, and metabolomic studies have examined the 
differences between early and advanced stage HNSCC [34, 40-46]. However, these 
studies have yielded mixed results overall. Some identified discriminatory features 
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between early and advanced stage samples, while others did not. Moreover, some models 
for similar endpoints, using the same data type, identified non-overlapping feature sets.  
Therefore, a key challenge in computational HNSCC research is effective data 
integration. Integration can occur both within and between –omic levels: by combining 
data of similar types across platforms (e.g., protein expression array and protein 
expression measured via mass spectrometry), or by combining different types of data 
(e.g., protein and gene expression data). Within –omic levels, some heterogeneity among 
datasets is expected due to experimental protocol- and platform-related factors; however, 
agreement is expected among fundamental putative biomarkers. Between –omic levels 
(e.g., genes and proteins), greater variation is expected because of the complex regulatory 
effects involved [47]. Better understanding of the key molecular features at each –omic 
level can provide insight into how these diverse molecular species collectively drive 
overall disease progression. Consequently, models which harness multiple types or levels 
of –omic data could provide better predictive performance and clinical utility.  
1.2.3. Combination Strategies for Chemoprevention  
Advances in –omic data acquisition and analysis have highlighted the importance 
of many signaling and metabolic pathways in HNSCC. As a result, molecularly targeted 
agents are emerging as a complement to conventional chemotherapeutics [2, 48]. 
However, due to factors such as pathway cross-talk, the response to individual targeted 
therapies has been limited, while those of combination therapies are promising. Some of 
these targeted agents, such as erlotinib and celecoxib, are also being applied for 
chemoprevention, in order to delay or prevent cancer progression [49, 50]. While these 
adjuvant chemoprevention therapies have shown promising effects in initial trials, 
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toxicity is a limiting factor. Therefore, the ongoing development of non-toxic agents for 
chemoprevention derived from natural dietary compounds, such as fruits and spices, is an 
important research direction [51, 52]. Aside from non-toxicity, one of the key strengths of 
these natural compounds, such as (-)epigallocathecin gallate (EGCG) from green tea, is 
that they are multi-target, interacting with key signaling pathways in complex manners. 
Moreover, combinations of natural compounds have demonstrated synergistic effects that 
can help compensate for limiting factors like low bioavailability [53-56].  
Observations regarding individual versus combination strategies indicate that for 
predicting therapeutic and chemopreventive outcomes, it is insufficient to only identify 
molecular biomarkers. It is also necessary to gain a “systems-level” understanding of 
their roles in the context of signal transduction and metabolic pathways. This paradigm of 
data mining followed by modeling reflects the data  information  knowledge  
action pipeline in Big Data research, since a system model is a higher-level representation 
of biomarker knowledge. Quantitative representations of cancer cell population and 
tumor growth have a long history in cancer research [57, 58]. In particular, the 
developing area of multi-scale cancer modeling explicitly links molecular-level 
observations, such as up-regulation of particular enzymes, to higher-level pathologically 
observed features, such as tumor aggressiveness. These representations are important for 
understanding system behavior and responses [59, 60]. However, previous modeling 
studies for HNSCC have focused on radiotherapy and chemotherapy, not targeted or 
multi-target therapeutic agents. Therefore, a key challenge is to develop a multi-scale 
modeling framework for HNSCC that can effectively predict the effects of combining 
multi-target agents.  
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1.2.4. Mathematical Modeling to Accelerate Translational Research 
Mathematical modeling approaches are critical for addressing the challenges 
discussed in the preceding sections. The proposed solutions to these challenges are 
categorized into three main focus areas: (1) knowledge-driven mining, (2) data 
integration, and (3) system modeling. These approaches are all critical for handling the 
volume, variety, and velocity characteristics of Big Data. First, because of the volume 
and velocity of –omic data acquisition, modeling contributions that utilize existing 
knowledge to guide mining can help ameliorate the bottleneck imposed by analyzing 
large datasets. Second, data integration approaches are necessary for extracting 
knowledge from the volume (within –omic data types) and variety (between –omic data 
types) of large biological datasets. Lastly, system modeling provides a higher-level 
organization to the knowledge obtained through knowledge-driven data mining and data 
integration, and can generate specific, quantitative, and testable predictions. 
1.3. Proposed Study and Organization of Dissertation 
This dissertation focuses on addressing the three previously described key 
challenges related to HNSCC progression and chemoprevention. This is accomplished by 
developing mathematical models for data mining and for predicting system dynamics. 
The Specific Aims of this research are: 
1. Knowledge-Driven  Data Mining: To develop modeling tools to mine  –omic  





Figure 1.5: Workflow of Dissertation Research 
 
2. Integrated –Omic Modeling: To develop supervised learning models for 
predicting HNSCC  progression through integration of –omic datasets 
3. System Modeling: To develop dynamic system models for predicting response to 
combinations of multi-target agents against HNSCC 
In combination, this suite of modeling tools accelerates knowledge extraction 
from –omic Big Data in HNSCC.  Chapter 2 of this dissertation focuses on Knowledge-
Driven Data Mining, through the development of similarity measures applicable to 
multiple –omic data types. Chapter 3 also addresses Knowledge-Driven Data Mining, but 
focuses on constructing a system specifically for mining metabolomic data. Chapters 4 
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and 5 are focused on Integrated –Omic Modeling. Chapter 4 develops models for 
predicting HNSCC pathological stage by integrating transcriptomic and proteomic data. 
Chapter 5 proposes models for early detection of HNSCC through the integration of 
multiple transcriptomic datasets. Chapter 6 addresses System Modeling by developing 
multi-scale models for predicting the response to natural compound adjuvants for 
HNSCC chemoprevention.  
Figure 1.5 describes the overall workflow of this dissertation, including the 
Specific Aims, the data types considered, and the developed models and tools. Chapter 7 
concludes the dissertation by summarizing the key deliverables, including publications, 

















SIMILARITY MEASURES FOR EXPLORATORY DATA MINING  
2.1. Applications of Similarity in Biomedical Research 
Similarity measures are an important tool in the analysis of a wide range of 
biomedical data, with applications such as comparing peptide sequences [61] and gene 
expression data [62], as well as in text mining [63] and in image analysis [64, 65]. An 
important application of similarity measures is the detection of new and potentially 
functionally relevant patterns in large-scale biological datasets [62, 65, 66]. For example, 
if a particular gene is known to be associated with a disease, other genes potentially 
related to the disease may be detected by identifying highly similar patterns of 
expression. In this respect, similarity measures can be used to provide a shortlist of 
targets for further research.  
Different similarity measures exhibit considerable variation in properties and 
performance [67, 68]. For example, many common measures do not have a probabilistic 
framework, although this is a useful property in terms of the interpretation of assigned 
similarity scores [69]. In this chapter, similarity measures with a probabilistic 
interpretation are proposed and developed. The first measure is restricted to two-class 
data, i.e., the comparison of binary images and data vectors. This model utilizes the 
hypergeometric distribution and Fisher’s exact test. However, many types of biological 
data are not inherently binary in nature, and the thresholding process can discard useful 
information. Thus, the second measure utilizes the multivariate hypergeometric 
distribution and the Fisher-Freeman-Halton test to extend the first model to accommodate 




2.2. Introduction to Mass Spectrometry Imaging 
Mass spectrometry imaging (MSI) data is used several times in this chapter for 
testing the similarity measures, due to the unique combination of molecular and 
morphological information it provides. It is also used in Chapter 3. Therefore, this section 
provides a brief introduction to MSI in order to facilitate interpretation of later results. 
MSI is an extension of conventional (non-imaging) mass spectrometry that can 
yield spatially-resolved information about the molecular composition of a biological 
sample. MSI datasets are generated by acquiring the complete mass spectrum at multiple 
points across the sample surface, yielding a three-dimensional (x,y: spatial dimensions, 
e.g. tissue, and z: spectral dimension) dataset as shown in Figure 2.1. The MSI dataset 
includes valuable information which is not obtainable through similar analyses using 
immunohistochemistry staining or conventional mass spectrometry. In traditional 
histological analysis, tissue is typically stained for a small number of molecular targets. 
In contrast, MSI is capable of simultaneously tracking thousands of m/z (mass-to-charge 





Figure 2.1: (left) Three-dimensional structure of MSI data. (right): False-color 
visualizations of multiple m/z values from MSI datasets of mouse models of Tay-
Sachs/Sandhoff disease. 
 














interpreted as a molecule or molecular fragment. Additionally, staining can only identify 
known molecular targets, while the large-scale data acquired by MSI enables discovery 
of sample components (and hence, potential biomarkers). Compared to mass 
spectrometry alone, MSI preserves the sample’s spatial and morphological information. 
Thus, spectra corresponding to different regions of tissue samples like biopsies (e.g., 
tumor, marginal, or normal regions) can be differentiated, enabling more detailed and 
target-specific analysis. Due to these benefits, MSI is emerging as a popular experimental 
technique in proteomics [70], lipidomics [71], and metabolomics [72] research.  
Because MSI is spatially-resolved, it is particularly relevant for research into 
diseases which have spatially localized characteristics – such as cancer. Recent MSI 
studies have investigated HNSCC [73], as well as cancers of the brain [74], breast [75], 
kidney [76], stomach [77], prostate [78], colon [79], pancreas [80], and bladder [81]. 
Other recent MSI studies have targeted diseases including Tay-Sachs/Sandhoff disease 
[82], Behçet disease [83], Parkinson’s disease [84, 85], Alzheimer’s disease [86], 
Duchenne muscular dystrophy [87, 88], Fabry disease [89], atherosclerosis [90] and 
stroke and ischemic injury [91-93]. In addition, MSI has been used to study bio-implant 
interfaces [94, 95] and drug distribution within tissues [96-101].  
The spectral dimension of MSI data can be very large (e.g. tens of thousands of 
m/z values), making computational analysis essential to interpretation. Thus, it is critical 
to identify and to develop effective analytical methods for large-scale data mining and 
pattern recognition to effectively utilize MSI data. I have discussed the current state-of-
the-art in MSI analysis techniques, including dimensionality reduction (e.g., principal 
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component analysis), clustering, and classification, in [102], but this content is outside 
the scope of this dissertation.  
2.3. Binary Hypergeometric Similarity Measure  
 In this section, a binary similarity measure is proposed and developed, using the 
hypergeometric distribution and Fisher’s exact test as a basis. The hypergeometric 
distribution has previously been used in bioinformatics to assess similarity in microarray 
functional analysis and tandem mass spectrometry [103-105]. The proposed 
hypergeometric similarity measure is compared with cosine similarity and Pearson 
correlation in terms of desirable properties related to formulation and behavior. Cosine 
similarity and Pearson have previously been used to assess similarity in mass 
spectrometry data for tasks ranging from protein identification to quality control [106-
110]. The performance of the proposed similarity measure on synthetic data and 
experimental MSI data is studied, and examples are provided to demonstrate its 
advantageous performance in identifying and ranking similarities.  
 
Desirable Properties of a Similarity Measure 
 The proposed similarity measure should sufficiently meet the following properties 
related to design and performance. The similarity measure should (1) be monotonically 
increasing between [-1, 1], in order to facilitate interpretation and comparison with other 
measures; (2) have good power of discrimination, i.e., should identify differences where 
they exist; (3) be consistently defined, i.e., there should not be sets of valid (observable) 
inputs for which the similarity measure output is undefined, and valid inputs should 
utilize the full dynamic range of the output. 
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Definition of Similarity Measure 
Consider a dataset consisting of i = 1, 2 … m vectors     
 . The reference 
vector    contains n1 dimensions with intensities greater than a selected threshold. When 
converted to binary form with respect to some threshold, this vector will have n1 ‘on’ 
dimensions and N - n1 ‘off’ dimensions, which can be represented ‘1’ and ‘0’, 
respectively. A second, query vector    has n2 ‘on’ dimensions. The total number of 
dimensions at which both images are ‘on’ is k. The significance of overlap can be defined 
in terms of the probability of observing k given N, n1, and n2. If k of the n1 dimensions 
from the first vector overlap k of the n2 dimensions from the second vector, those k 
dimensions in the first vector may be arranged in (  
 
) ways. In the second vector, the    
(n2 - k) dimensions which do not overlap may be arranged in (
    
    
) ways. Thus, the total 
number of ways in which an overlap of k dimensions can occur, given n1, n2 and N, 
is (  
 
) (    
    
). When divided by the number of ways in which the n2 ‘on’ dimensions in 
the second vector could be arranged if k of them were not constrained, this becomes the 
pmf of the hypergeometric distribution. I propose a similarity measure h(k,n1,n2,N) which 
is defined, for any valid k, as the difference between the lower and upper “tails” of the 
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The cumulative distribution function (cdf) of the hypergeometric distribution has 
previously been utilized as a similarity measure [111]. Since the population is discrete, 
additional information about k may be obtained by considering the probability of 
observing overlap at least as extreme. Both of these quantities can be considered p-values 
of hypothesis tests. In both cases, the null hypothesis H0 is that the observed overlap 
occurred by chance. This is described by the urn model, in which an urn contains marbles 
of two colors, one representing a pair of overlapping ‘on’ pixels and the other 
representing non-overlap. When n2 marbles are drawn from the urn without replacement 
and k of them are of the color representing overlap, the null hypothesis states that this has 
occurred by chance. The alternative hypotheses are that the observed overlaps are, 
respectively, larger or smaller than would be expected to occur at random for such an 
image pair. This implies that the images may be related, i.e., notably similar or dissimilar. 
Through the difference between these two probabilities, the proposed measure provides a 
scaled description of the unexpectedness of any observed overlap. The “tails” of the 
hypergeometric distribution also have upper bounds [112, 113]. For some parameter sets 
tested, the value of the hypergeometric pmf may be so small as to encounter machine 
resolution limits. Then, the proposed similarity measure may be implemented in terms of 
the upper bounds, as shown in equation (2.2).  
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   ), such that t2 ≥ 0.  
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Similarity Measure Comparison and Assessment 
First, the cosine similarity and Pearson correlation for binary vectors are 
expressed with the same variables as the hypergeometric pmf, allowing direct comparison 
of their formulae. Similarities and differences among the measures may be observed 
through their formulae; the binary expressions for cosine similarity and Pearson 
correlation are shown in equations (2.3) and (2.4). These are derived by noting that for 
binary vectors V1 and V2, the dot product is equivalent to k, and the norms to √   and 
√  . Equation (2.4) is equivalent to Matthews correlation coefficient (MCC) [111, 114]. 
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Performance on Synthetic and MSI Data 
First, considering the mathematical expressions for each similarity measure, both 
cosine similarity and Pearson correlation are both linear with respect to k, and behave 
nonlinearly with respect to n1 and n2. Cosine similarity is independent of N, while mean-
centering in Pearson correlation brings N into consideration. Pearson correlation 
asymptotically approaches cosine similarity for large N. The proposed measure, like 
Pearson correlation, considers N, but like cosine similarity, does not mean-center the 





Figure 2.2: Hypergeometric similarity measure (solid), cosine similarity (dot) 
and Pearson correlation (dash) for N = 100, n1 = n2 = 50. 
 
Second, the proposed similarity measure is compared with the cosine similarity 
and Pearson correlation by evaluating their output for binary image pairs having varying 
degrees of overlap. Figure 2.2 demonstrates that the proposed similarity measure satisfies 
criterion (1) regarding the desired properties of monotonicity and range. The 
hypergeometric similarity measure and Pearson correlation share a range of [-1, 1], while 
for positive data the range of cosine similarity is [0, 1]. The extremes of the 
hypergeometric similarity measure represent the limits of observable overlap k for a 
given parameter set N, n1 and n2. 
Third, a synthetic dataset of binary vectors (images) with dimension N = 10 was 
created by considering all combinations of n2, n1 and k such that N ≥ n2 ≥ n1 ≥ k, and such 
that k is greater than or equal to its minimum for any given n1, n2 and N (i.e., k ≥ n1 + n – 
N). This dataset consists of 150 vector pairs. The three similarity measures were  






























   
Pearson correlation Cosine similarity Hypergeometric similarity measure 
Figure 2.3: Vector pair description (l) and corresponding similarity measure score (r). Color 
coding for the vector pair segments is as follows. Dark gray: k, number of overlapping ‘on’ 
pixels. Black: n1 - k, number of non-overlapping ‘on’ pixels in image 1. Light gray: n2 - k, 
number of non-overlapping ‘on’ pixels in image 2. White: N - n1 - n2 + k, total number of 
‘off’ pixels. All vectors have length N = 10. 
 
evaluated for each pair, and their outputs compared in terms of relative rankings. Figure 
2.3 shows the performance of the similarity measures over the synthetic dataset. 
The rankings show that the proposed similarity measure fulfills criterion (2), 
which addresses discrimination of differing cases. In particular, I examine the extreme 
cases of (a) no overlap, (b) complete overlap and (c) ‘unsurprising’ overlap. (a) Cosine 
similarity assigns 0 to all vector pairs with no overlap; a large segment of the dataset is so 
labeled with no additional sorting. Pearson correlation and the proposed similarity 
measure both sort this subset of vectors. However, only the proposed similarity measure 
recognizes that k = 0 is more surprising when n1 approaches n2, because there is more 
opportunity for at least some overlap. (b) The treatment of cases with complete overlap (k 
= n1 = n2) is also favorable with the proposed similarity measure because it orders them 
in a meaningful manner. It identifies k = 5 as the most ‘surprising’ case of complete  









































Figure 2.4: Fraction agreement between similarity measure and manual m/z selections 
across percentile-based binarization thresholds. 
 
overlap, since there are the most opportunities for non-overlap to occur. The probability 











). It also recognizes that k = 6 and k = 4 are 
equally ‘surprising’, since the probability of arranging n2 = 6 pixels to completely overlap 
n1 = 6 pixels is the same as arranging (N – n2) = 4 pixels to completely overlap (N – n1) = 
4 pixels. The same pairings are observed for k = 7 and k = 3, and k = 8 and k = 2. In 
contrast, both cosine similarity and Pearson correlation assign 1 to this entire subset of 
vectors without further sorting. (c) The proposed similarity measure also meets criterion 
(3) regarding definition over the parameter space.  Pearson correlation is not defined for 
vector pairs in which n1 = N or n2 = N; this is evident from equation (4). The proposed 
similarity measure assigns 0 to these cases, because by definition, k = n1. Thus, even 
though complete overlap occurs, it is not unexpected.   























































Fourth, the similarity measures were implemented on a biological MSI dataset. 
Although HNSCC tissue has previously been assessed using MSI [73], such data is 
currently not available to me for analysis. Instead, MSI data from a mouse model of Tay-
Sachs/Sandhoff disease was used to test the similarity measure. Since general data 
characteristics for particular types of MSI data (e.g., MALDI, DESI, etc.) are expected to 
be similar regardless of the target tissue, it is reasonable to extrapolate conclusions to 
future performance on HNSCC MSI data. The experimental protocol for the MSI dataset 
investigated here is described in [82]. The image corresponding to m/z 890 was selected 
as a reference to due to its distinctive spatial pattern. The MSI dataset has a spectral 
dimension of 4,438 m/z values. It was manually inspected in non-binary mode to identify 
m/z values with similar spatial patterns; 47 m/z images were selected. The top 47 values 
selected by each similarity measure were compared to these values. The correspondence 
of the two lists was calculated for each similarity measure, and repeated for 11 alternative 
binarization thresholds. The upper bounds formulation shown in equation (2.2) used in 
this assessment due to the large variable values involved.  
Figure 2.4 describes similarity measure performance, assessed as the fraction 
agreement between the top m/z values selected by each similarity measure and the 
manual selections. This comparison was carried out across multiple binarization 
thresholds based on the abundance percentiles of the mean spectrum. For this dataset, the 
90
th
 percentile yields top selections from the similarity measures which correspond most 
closely to the manual selections. The selections of the proposed measure and Pearson 
correlation correspond highly with the manual selections, and also with each other. The 
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selections of cosine similarity consistently differed from the other two, and from the 
manual selections.  
 
Discussion and Limitations of Binary Approach 
In summary, a hypergeometric similarity measure is proposed as a tool for the 
exploration and analysis of biomedical data. Due to its definition as the difference 
between the upper and lower “tails” of the hypergeometric distribution, the proposed 
similarity measure explicitly defines the unexpectedness of any observed overlap. Using 
synthetic data, the proposed similarity measure was compared with cosine similarity and 
Pearson correlation in terms of three criteria related to design and performance, and it 
was shown to perform favorably. Tests on a biological, non-HNSCC MSI dataset showed 
that the proposed similarity measure is effective in identifying visually notable spatial 
similarities. Together, these results indicate that the proposed similarity measure can play 
a useful role in assessing similarity in biomedical data.  
However, several caveats remain. First and foremost, abundance is a key feature 
of biological data, and analyzing binary data ignores this information. In the MSI dataset 
examined here, analysis of binarized data still revealed informative patterns. However, 
for some HNSCC datasets, retaining abundance information may be necessary for 
meaningful analyses. The flexibility to accommodate abundance to some extent is 
particularly important for the goal of developing a general similarity measure that 
provides useful output for multiple HNSCC –omic data types. Second, if binary data is to 
be used, the selection of appropriate thresholds to convert non-binary data to binary data 
is an open problem. Many alternative methods for thresholding images have been 
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proposed in image processing [115]. Results on this particular biological dataset indicated 
that increasing the threshold can increase agreement with the set of manually selected m/z 
values. However, the potential effects of inter-dataset variation on the performance of all 
three similarity measures have not yet been studied. That investigation would provide 
more insight into threshold effects and lead to more systematic recommendations for 
specific data types.  
Instead, the next section in this chapter addresses this issue directly, by modifying 




















2.4. Multivariate Hypergeometric Similarity Measure  
In this section, the previous result is extended to present a general similarity 
measure that accommodates the comparison of non-binary, “multi-class” data. After 
defining the proposed multivariate hypergeometric similarity measure, I describe several 
tests using synthetic and biological data to investigate its performance. First, its patterns 
of sample ranking are again compared with those of cosine similarity and Pearson 
correlation, as well as with mutual information. These three similarity measures are used 
in the analysis of many types of biomedical data [62-65, 116]. Next, an algorithm called 
piecewise approximation, which facilitates the application of the proposed similarity 
measure to large samples, is developed and implemented. 
 
Definition of Similarity Measure 
Consider a dataset consisting of z = 1, 2 … m vectors     
 , with all intensities 
quantized into n bins, where N and n are positive integers. When comparing two such 
vectors, there are n
2
 possible types of overlap between corresponding dimensions (i.e., in 
images, for spatially corresponding pixels). These overlaps can be represented as an 
    contingency table, as shown in Figure 2.5. Each class kij, for indices i = 1...n and j 
= 1...n, represents the number of corresponding dimensions which are in bin i in the first 
(“reference”) vector and in bin j in the second (“query”) vector. The terminology is used 
in the sense that a given sample of interest would be selected as a “reference” and other 
samples in a dataset would be compared, or “queried” against it to find samples similar to 
the reference. The margins of the contingency table are fixed for a given pair of images: 
for each row i, ∑    
 




Figure 2.5: An image pair (reference and query images) with pixels intensities binned 
into three levels is represented as a 3 3 contingency table with fixed marginal totals. 
 
similarly for each column j, ∑    
 
       , the number of pixels in bin j in the query 
image. By definition, ∑        . The probability of observing a particular distribution 
of overlaps kij, i.e., the probability of observing a given contingency table, can be 
represented as the product of probability mass functions of the multivariate 
hypergeometric distribution. Considering only the first column of an n   n contingency 
table with row marginal totals ri, the column sum is q1 = k11 + k21 + . . . kn1. Each 
component ki1 is drawn from its row sum ri. Since each draw is independent, the 
probability of observing a particular distribution of pixels is given as 
(
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) (
  
   
)
(   
)
. This 
quantity is a probability mass function of the multivariate hypergeometric distribution. 
The probability of observing the second column is described similarly, but accounts for 
the pixels already assigned in the previous column: 
(
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(      
)
. The same 
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pattern is followed through the (n – 1)
th
 column. Because the row and column sums are 
fixed, the configuration of the n
th
 column is determined by the preceding columns. Since 
the configuration of the available dimensions in each column (aside from the n
th
 column) 
is independent of the other columns, the probability p of the complete n × n contingency 
table is given by the product of the column probabilities. This quantity, shown in 
equation (2.5), is known as the probability for k-variate contingency tables [117, 118]. 
Here  q  =  [ q 1 ,  q 2  … q n ] ,  r  = [ r 1 ,  r 2  … r n ]  and  k  = [k 1 1 ,  k 1 2  . . .  k n n ] . 
         
∏     ∏    
 
   
 
   
    ∏       
 (2.5) 
In previous work focusing on binary data, the similarity measure was defined 
based on the hypergeometric distribution; the probability mass function of this 
distribution gives the probability of a 2   2 contingency table [119]. The similarity 
measure was defined as the difference between the lower and upper “tails” of the 
hypergeometric distribution defined by the marginal totals r and q. The values of r and q 
are a function of the particular reference image and query image being compared. The 
“tails” were defined with respect to the observed overlap, which was defined as the 
number of spatially corresponding pixels which are ‘on’ in both images, i.e., k11 in this 
terminology. To extend this approach from the two classes in binary data to n classes, I 
utilized the probability mass function of the n × n contingency table.     
The statistical significance of a contingency table is evaluated by performing 
Fisher’s exact test (in the binary case) or the Fisher-Freeman-Halton test (in the general 
case) [117, 120]. In both cases, the isomarginal family of tables (i.e. those tables having 
the same fixed margins r and q as the original table representing the reference and query 
image pair) is first generated, and the probability of each table within this family is 
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calculated. In the binary case, the hypergeometric distribution describes the isomarginal 
family. For each table in the isomarginal family, the value of a chosen statistic S(k) is 
compared to that of the original table. With respect to S(k), tables in the isomarginal 
family may be more extreme than the original table in two directions. The set of tables 
which are “more extremely large” have a larger than or equal value of the statistic, while 
the set of tables which are “more extremely small” have a smaller than or equal value of 
the statistic. The significance of a table in a particular direction is found by summing the 
probabilities of all tables within the respective set.  
In the binary case, the choice of the statistic S(k) is straightforward because due to 
the fixed margins, there is only one degree of freedom. S(k) = k11 completely defines the 
table, and is reasonable because more similar images will have greater numbers of 
overlapping pixels. In the general case, however, there are n
2
 – 2n + 1 degrees of 
freedom, and for n > 2, the choice of a statistic is not obvious. Here, I choose a vector of 
statistics – the set of diagonal elements of the n   n table – as S(k), as shown in equation 
(2). These diagonal elements represent the exact matches – the spatially corresponding 
pixels in the reference and query images which are in the same class. While S(k) may be 
defined in many alternative ways, I propose equation (2.6) as a reasonable choice for 
multi-class data because images which are more similar will have a greater number of 
each of the n types of exact matches. 
     [             ] (2.6) 
 
For each table in the isomarginal family, I performed an index-wise comparison 
of each diagonal element to the corresponding diagonal element in the original table. In 
other words, I compared each element in S(k) with the corresponding element in S0, 
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which is the instance of S(k) observed for the original table. If each diagonal element in 
the table is greater than or equal to its corresponding element in S0, the table is assigned to 
set G, the set of “more extremely large” tables with respect to all elements of S(k). If each 
diagonal elements is less than or equal to its corresponding element in S0, the table is 
assigned to set L, the set of “more extremely small” tables. Equation (2.7) defines the 
proposed multivariate hypergeometric similarity measure h in terms of the probabilities 
of the tables in these two sets. 
  ∑        
 




Comparison of Similarity Measures 
The sample rankings obtained from the proposed measure are compared with 
those from cosine similarity, Pearson correlation, and mutual information. Cosine 
similarity and Pearson correlation are defined for vectors V1 and V2 in equations (2.8) and 
(2.9), respectively. Mutual information is defined in (2.10), where xi and yj are the 
elements of V1 and V2, respectively. 
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 Design of Synthetic Dataset 
First, the performance of the multivariate hypergeometric similarity measure is 
evaluated on synthetic data. While the proposed similarity measure is defined for any n ≥ 
2 classes, these synthetic experiments are performed using only three classes to clearly 
illustrate the method. Two synthetic datasets are used for this comparison. The first 
consists of the three-class isomarginal family defined by marginal totals (r1, r2, r3, q1, q2, 
q3) = (5, 5, 5, 5, 5, 5) and N = 15. The second consists of all three-class tables with N = 5.  
2.4.1. Piecewise Approximation 
Testing the significance of n × n contingency tables obtained from biomedical 
data, such as MSI data, poses a challenge due to data size. As the numbers of pixels in the 
images, and hence the marginal totals, increase, generating the isomarginal family of 
tables to perform the Fisher-Freeman-Halton test becomes demanding. The number of 
possible tables increases factorially as the numbers of rows, columns or total pixels 
increase [121, 122].  As an analytical example, the number of three-class contingency 
tables where all rows and columns sum to r is given by (   
 
)   (   
 
) [123, 124]. When 
faced with a very large number of tables to enumerate in the isomarginal family, 
approximate solutions can be found through Monte Carlo testing [120]. However, in 
practice this may demand very large numbers of permutations to achieve satisfactory 
separation of similarity rankings. 
Here I propose a piecewise method of approximation, in which the two images or 
data vectors to be compared are divided into a number of smaller subsections. The 




Figure 2.6: Overview of piecewise approximation process: subsection (1.) corresponds to 
the top-left 4x4 blocks of the reference and query images; (2.) to the 4x4 blocks to the 
immediate right of (1.); and (n.) to the bottom-right 4x4 blocks. The similarity is 
calculated for each spatially corresponding reference and query section, and the overall 
similarity of the reference and query is calculated as a function of the sub-section scores. 
 
For each pair of reference and query subsections, an n × n contingency table is 
constructed and the multivariate hypergeometric similarity measure is calculated. The 
overall similarity of the image pair is computed as a function of the similarities of all 
subsections. Figure 2.6 illustrates this process.  
Piecewise approximation requires choices in how images or data vectors are 
separated into subsections (e.g., different subsection sizes) and how the similarity scores 
for the subsections are combined to obtain an overall similarity score for the image pair 
(e.g., different functions). Alternative choices are examined here through experiments on 
synthetic and biomedical data. First, the previously described synthetic dataset (for N = 
15) is used to examine whether there is a pattern between subsection size and the extent 
of difference observed between the piecewise approximation rankings and the exact 
rankings. In this test, the rankings for each sample obtained by using subsections of size 
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3, 4 and 5 pixels are compared with the ranking calculated using the whole sample. To 
avoid the comparison of single-pixel sections, if the sample is not evenly divisible at a 
particular increment size, the remainder pixels are added to the previous subsection to 
create one subsection larger than the others. In the same experiment, the effect of 
permuting the reference and query samples which correspond to a single n × n table is 
considered. While a given pair of samples yields a single n × n table, mapping a given 
table back to the sample space yields non-unique indexing of spatially corresponding 
pixels. This type of indexing difference would not affect the similarity score of a given 
reference and query pair if the whole sample is utilized. However, when piecewise 
approximation is employed, different subsections may contain different proportions of 
the pixels for each type of overlap kij. To examine how this may affect results, the 
‘randperm’ function in MATLAB was used to generate a permutation of the sample 
indices, which was applied to both the reference and query samples before they were 
divided into subsections. This was repeated 10,000 times. The purpose of this step is to 
confirm that overall sample rankings in the synthetic dataset are not an artifact of 
arbitrary methods of generating synthetic samples from tables and subsectioning samples. 
For each subsection size, the sample ranking results shown are the mean across all 
permutations. Next, biomedical data was used to empirically compare alternative 
functions for aggregating the subsection similarity scores into an overall score for the 
image pair.  
2.4.2. Performance on Synthetic Data 
This section describes two sets of results. First, the performance of the proposed 
multivariate hypergeometric similarity measure is compared with the other similarity 
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measures using synthetic data. Second, the effects of subsection size and combination 
functions on the piecewise approximation method are investigated using synthetic and 
experimental MSI data.  
In the first set of results, the rankings of samples in synthetic datasets by the three 
similarity measures are compared in Figures 2.7 and 2.8. Each sample (horizontal bar) 
 





Figure 2.7: Comparison of sample rankings by the four similarity measures for the synthetic 
dataset comprising the isomarginal family given by (r1, r2, r3, q1, q2, q3) = (5, 5, 5, 5, 5, 5). Each 
sample (horizontal bar) represents a certain number of exact matches, slight mismatches and 
large mismatches (corresponding to [green, yellow, red], or [medium, light and dark] in 
grayscale). The length of each color segment corresponds to the number of that type of match in 
the sample. For each similarity measure, the similarity score corresponding to each sample is 
shown on the right panel. 


















































































represents a single table, with the green, yellow and red segments representing the 
number of exact matches (k11 + k22 + k33), slight mismatches (k12 + k21 + k23 + k32) and 
large mismatches (k13 + k31), respectively. In Figure 2.7, there are 231 tables represented; 
these tables comprise the isomarginal family defined by marginal totals (r1, r2, r3, q1, q2, 
q3) = (5, 5, 5, 5, 5, 5).  
All three similarity measures agree in that the highest score is assigned to the 
table with the largest number of exact matches. None of the similarity measures are 
monotonic with respect to the number of exact matches, but rankings from the proposed 
similarity measure are much closer to this trend than rankings from cosine similarity and 
Pearson correlation. Cosine similarity and Pearson correlation more closely sort by the 
number of large mismatches. For a single isomarginal family, the magnitudes and means 
of the two vectors are constant. The rankings of cosine similarity and Pearson correlation 
therefore depend on the value of the dot product, and the minimum dot product is 
observed when the number of large mismatches is maximized. The proposed similarity 
measure does not provide such distinction between slight and large mismatches, but it 
does provide a probabilistic interpretation which cosine similarity and Pearson correlation 
do not: the samples associated with extreme scores are the most “surprising” patterns of 
overlap observed.  Mutual information assigns higher scores to cases where most pixels 
are concentrated in a few classes, but does not differentiate among the classes. For 
example, the tables with [k11, k22, k33] = [5,5,5] (i.e., all exact matches) and [k31, k22, k13] 
= [5,5,5] (i.e., many large mismatches) both receive equally high scores; as a result, the 
mutual information results do not show any trend with respect to exact matches, slight 
mismatches or large mismatches. In contrast, [k11, k22, k33] = [5,5,5] is ranked highly by 
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the proposed similarity measure, while [k31, k22, k13] =  [5,5,5] receives a much lower 
score. 
Figure 2.8 considers the rankings of the 1287 tables generated by considering 
every possible combination of marginal totals such that (r1 + r2 + r3 = 5) and (q1 + q2 + q3 
= 5). Again, all of the measures agree in that the highest score is assigned to the table 
with the largest number of exact matches, but the proposed similarity measure more 
consistently assigns lower scores to tables with fewer exact matches. The rankings in this 
 
Pearson correlation Cosine similarity Mutual information Hypergeometric 
similarity measure 
Figure 2.8: Comparison of sample rankings by the four similarity measures for the synthetic 
dataset containing all tables for N = 5. Each sample (horizontal bar) contains a certain number 
of exact matches, slight mismatches and large mismatches (corresponding to [green, yellow, 
red], or [medium, light and dark] in grayscale). The length of each color segment corresponds 
to the number of that type of match in the sample. For each similarity measure, the similarity 
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set of all tables for N = 5 illustrate additional probabilistic aspects of the proposed 
similarity measure. For example, the proposed measure can distinguish between instances 
of overlap with different distribution magnitudes. It assigns identical scores to the set of 
tables with [k11, k22, k33] as [3,1,1], [1,3,1] and [1,1,3], and a different identical score to 
the other possible set of tables describing only exact overlap, with [k11, k22, k33] as 
[2,2,1], [2,1,2] and [1,2,2]. Pearson correlation and cosine similarity do not distinguish 
between these two sets of tables. Mutual information distinguishes the two sets of tables, 
but again does not distinguish between case cases of exact matches and many large 
mismatches; for example, the cases where [k11, k22, k33] = [3,1,1] and [k31, k22, k13] = 
[3,1,1] are assigned the same score, and [k11, k22, k33] = [2,2,1] and [k31, k22, k13] = [2,1,2] 
are assigned the same score. For a second example, in the proposed measure, all tables 
which have marginal totals such that only one n   n table is possible are mapped to a 
score of zero. If only one set of overlaps kij can be observed for a particular pair of 
images or data vectors, then the overlap which is observed can be considered inherently 
“unsurprising.” In contrast, this set of tables is undefined for Pearson correlation (i.e., 
these tables are assigned the value NaN, as shown at the top of the Pearson correlation 
plot in Figure 2.8). Cosine similarity does not group these tables together or otherwise 
distinguish them. 
In the second set of results, the effects of subsection size on the piecewise 
approximation result are described in Figure 2.9. The 231 samples in the synthetic dataset 
shown in Figure 2.7 are plotted in order of increasing exact score. The piecewise 
approximation scores for each sample, across increments of size 3, 4 and 5, are 




Figure 2.9: The mean rankings of synthetic samples using piecewise approximation at 
different subsection sizes (size 3: blue dash-dot line; size 4: green dotted line; size 5: red 
dashed line) compared to rankings from using the whole sample (black, solid line). 
 
reference and query vectors is shown. Overall, the piecewise approximation scores follow 
the trend of the exact score, but there are notable deviations. In such cases, samples are 
ranked higher or lower as an artifact of the piecewise sectioning process. Interestingly, 
these cases tend to correspond across all of the subsection sizes; if a sample was scored 
much higher or lower than its adjacent samples by the piecewise method, the same jump 
or dip in score was observed across all three subsection sizes. However, the magnitudes 
of the piecewise scores indicate that, as expected, larger sections give scores closer to the 
exact result.  
Next, different statistics for combining the similarity scores of subsections into a 
single overall score for the sample pair are compared empirically, using MSI data with a  











































Figure 2.10: Empirical comparison of alternative functions for combining subsection 
similarity scores into an overall similarity score through piecewise approximation. Each 
dot on the scatter plot represents one query image (m/z value); 4,438 are in the dataset. 
The value (image pair score) of the dot represents the similarity score assigned to the 
query image based on the specified function of its subsection scores. For example, in the 
‘mean’ plot, the image pair score of each query image is the average similarity score of 
its subsections. 
 
subsection size of 4 4 pixels for piecewise approximation. Figure 2.10 shows the image 
pair similarity scores for each of the 4,438 m/z values, computed as the mean, median, 
mode, variance, skewness or kurtosis of all of their subsection scores. The x-axis of these 
plots, showing indices 1 through 4,438, represents the query m/z images; each is 
associated with a single score (dot) on the y-axis. This score is obtained by evaluating the 
specified function (e.g., the mean) over the set of subsection scores obtained for that 
query image when it was compared to the reference image. To interpret these results, it is 
necessary to consider that the reference m/z image corresponds to index 783. Since the 
most similar image in the dataset to the reference image should be the reference image 
itself, a well-performing function should assign the most extreme score to this index. This 
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result is observed for the mean, median, variance and kurtosis functions. During previous 
study of this dataset for the binary measure, 47 of the 4,438 images were observed to be 
qualitatively very similar to the reference m/z image, and those images were observed to 
be associated with indices relatively close to the reference index [119]. In contrast, lower 
indices were associated with noisy images (an artifact of MALDI MSI data acquisition), 
and higher indices with sparse images. A well-performing function would therefore 
exhibit a peak centered at the reference index of 783. The mean and kurtosis both show 
this feature by assigning extreme (higher and lower than most others, respectively) scores 
to indices close to the reference index. 
2.5. Case Studies 
Two HNSCC datasets were examined in this study. The first was a gene 
expression microarray dataset consisting of 25 cancer patient samples. This dataset was 
obtained from the ArrayExpress repository (ID: E-GEOD-6791), and is described in 
[125]. This study used the Affymetrix Human Genome U133 Plus 2.0 array platform, 
which contains 54,675 probes. To obtain gene expression values, raw .CEL files were 
processed with the robust multi-array average (RMA) algorithm in the Affymetrix 
Expression Console software. The second was a protein expression dataset consisting of 
reverse phase protein array (RPPA) data available from The Cancer Proteome Atlas 
[126]. This dataset consisted of 212 cancer patient samples and described the expression 
of 187 proteins. For both of these datasets, EGFR (which is up-regulated in more than 
80% of HNSCC) was used as the reference gene and protein, respectively.  
In order to (1) further investigate the generality of the similarity measure 
performance, (2) test a metabolomics (lipidomics) dataset, and (3) provide an easy-to-
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interpret visual representation of performance, an MSI dataset was also investigated. This 
was the same experimental MSI data used previously, from a mouse model of Tay-
Sachs/Sandhoff disease, and used to profile different lipid species in the brain [82]. The 
image corresponding to m/z 889.6 (located at index 783 within the dataset) was again 
selected as the reference image due to its distinctive spatial pattern. The MSI data has a 
spectral dimension of 4,438 m/z values, and all m/z images were tested as query images 
against the reference image of m/z 889.6.  
For all of these datasets, the three-class cases were used for the experiments. 
Feature (gene, protein, m/z)-specific, percentile-based threshold pairs (x, y) were used to 
bin each expression value into “high” (> y), “medium” (x < and ≤ y) or “low” (≤ x) 
classes. For the gene and protein expression datasets, results from several alternative 
threshold pairs were compared. For the MSI dataset, the upper threshold y was arbitrarily 
selected as the 50
th
 percentile of the mean spectrum of the dataset, and the lower 
threshold x was 0. The piecewise approximation approach was used in all cases. For the 
gene and protein expression datasets, the primary subsection size was fixed at 10 
features. In the MSI dataset, a primary subsection size of 4 4 was chosen after testing 
several sizes in an effort to balance section size and computational time. The proposed 
similarity measure score was calculated for each subsection. For the gene and protein 
expression datasets, the average score across subsections was taken as the overall 
similarity for the feature pair. For the MSI data, two functions (the mean and kurtosis) for 
combining subsection scores into an aggregate image pair score were compared. Finally, 
for all datasets, the top features selected by the proposed similarity measure using three 
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classes were compared to the top three-class results for cosine similarity, Pearson 
correlation and mutual information. 
2.5.1. Gene Expression 
Tables 2.1-2.3 show the top 20 gene rankings for each of the similarity measures 
for a single EGFR reference probe across three alternative percentile-based thresholds. 
First, for all cases, the reference probe ‘211550_at’ is selected as the most similar, as it 
should be. Second, this set of results demonstrates that the multivariate hypergeometric 
similarity measure is successful in identifying genes which are associated with head and 
neck cancer. Moreover, across the three alternative thresholds considered, the proposed 
similarity measure identified 41 probes that were not in the top 20 rankings of the other 
similarity measures. Among these, 15 genes have been associated with head and neck 
cancer in recent studies: STX6 [127], BCL2L2 [128], RGS20 [129],  SSSCA1 [130, 131], 
EHD2 [132], SYNPO2L [133], CNR2 [134], HCRP1 [135], CSNK1G2 [136, 137], 
EFNB1 [138], SH3GL2 [139], KRT31 [140], FKBP1A [141], SLC7A8 [142], and 
BCL2L14 [143]. In addition, HIBADH [144] and DSG1 [145] have been associated with 
head and neck cancer on the protein level.  
These results also emphasize the value of integrating multiple forms of analysis in 
order to leverage complementary findings. One option is combining the results from 
alternative similarity measures. In addition, the benefits of examining a single dataset 
across alternative thresholds can be clearly observed through the notably different gene 
lists for each measure in Tables 2.1-2.3. Parallel assessments with different probes for the 
same gene are also important. For example, the top 20 rankings by the multivariate 
hypergeometric similarity measure for another EGFR probe gave relevant results such as 
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ITGBL1 [146] and TMCC1 [147]. Overall, these observations indicate that applying the 
multivariate hypergeometric similarity measure can yield relevant and useful results.  
 
Table 2.1: Top 20 rankings by similarity measures on head and neck cancer microarray 




Pearson correlation Cosine similarity Mutual information 
Probe Gene Probe Gene Probe Gene Probe Gene 





















































MIR31HG 1555183_at TERF2 231960_at BRWD1 









































PCDHGC3 242832_at PER1 
1552618_
at 























NEFL 228587_at FAM83G 220510_at RHBG 
211716_x
_at 
ARHGDIA 228587_at FAM83G 
230704_s_
at 
ITGB4 237361_at --- 
203411_s_
at 
LMNA 234894_at ITIH6 234743_at LIMD1 244233_at --- 
216060_s_
at 
DAAM1 241405_at LOC400604 234894_at ITIH6 203256_at CDH3 
206642_at DSG1 1555183_at TERF2 241405_at LOC400604 216293_at CLTA 
231955_s_
at 











Table 2.2: Top 20 rankings by similarity measures on head and neck cancer microarray 
data, using percentiles [25, 75] as thresholds 
Multivariate hypergeometric 
similarity measure 
Pearson correlation Cosine similarity Mutual information 
Probe Gene Probe Gene Probe Gene Probe Gene 
















































ELF5 203685_at BCL2 




















































BAHCC1 212462_at KAT6B 
204996_s_a
t 
CDK5R1 217308_at OR1F2P 
1559205_s_
at 
--- 213058_at TTC28 










































Table 2.3: Top 20 rankings by similarity measures on head and neck cancer microarray 
data, using percentiles [50, 75] as thresholds 
Multivariate hypergeometric 
similarity measure 
Pearson correlation Cosine similarity Mutual information 
Probe Gene Probe Gene Probe Gene Probe Gene 





































































































































































2.5.2. Protein Expression 
The similarity measure results for RPPA data are shown in Tables 2.4-2.6, for 
three alternative threshold selections. For all threshold selections – and for all similarity  
 
Table 2.4: Top 20 rankings by similarity measures on head and neck cancer RPPA data, 




Pearson correlation Cosine similarity Mutual information 
1 EGFR EGFR EGFR EGFR 
2 EGFR_pY1068 EGFR_pY1068 EGFR_pY1068 EGFR_pY1068 
3 E-Cadherin eEF2K eEF2K eEF2K 
4 eIF4G VHL VHL VHL 
5 VHL Akt Akt Akt 
6 HER2 p70S6K p70S6K E-Cadherin 
7 Akt beta-Catenin beta-Catenin Bap1-c-4 
8 eEF2K Tuberin Tuberin Tuberin 
9 Tuberin mTOR mTOR beta-Catenin 
10 c-Jun_pS73 E-Cadherin E-Cadherin p70S6K 
11 p70S6K ERK2 ERK2 ERK2 
12 Ku80 HER2 HER2 mTOR 
13 mTOR eIF4G eIF4G eIF4G 
14 beta-Catenin Bap1-c-4 Bap1-c-4 c-Met_pY1235 
15 PDK1_pS241 PDK1_pS241 PDK1_pS241 SF2 
16 INPP4B Chk1_pS345 Chk1_pS345 CD31 
17 c-Myc Ku80 Ku80 Bax 
18 ACC1 STAT5-alpha STAT5-alpha HER2 
19 B-Raf TSC1 TSC1 MEK1_pS217_S221 
20 ERK2 B-Raf B-Raf c-Kit 
 
Table 2.5: Top 20 rankings by similarity measures on head and neck cancer RPPA data, 




Pearson correlation Cosine similarity Mutual information 
1 EGFR EGFR EGFR EGFR 
2 EGFR_pY1068 EGFR_pY1068 EGFR_pY1068 EGFR_pY1068 
3 E-Cadherin eEF2K eEF2K eEF2K 
4 eEF2K VHL VHL CD31 
5 eIF4G Chk1_pS345 Chk1_pS345 VHL 
6 mTOR eEF2 eEF2 Bcl-2 
7 Tuberin beta-Catenin beta-Catenin PDK1 
8 HER2 mTOR mTOR DJ-1 
9 VHL PDK1_pS241 PDK1_pS241 14-3-3_epsilon 
10 p70S6K Tuberin Tuberin eIF4G 
11 ERK2 HER2_pY1248 HER2_pY1248 Akt 
12 Bap1-c-4 INPP4B INPP4B PEA-15 
13 TSC1 E-Cadherin E-Cadherin Bap1-c-4 
14 Chk1_pS345 eIF4G eIF4G beta-Catenin 
15 beta-Catenin p70S6K p70S6K eEF2 
16 Ku80 ERK2 ERK2 E-Cadherin 
17 Akt ACC1 ACC1 Tuberin 
18 GSK3-alpha-beta Paxillin Paxillin p70S6K 
19 PDK1_pS241 MEK1 MEK1 Chk1_pS345 
20 ACC1 Bap1-c-4 Bap1-c-4 p27 
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measures – the top-ranked protein was EGFR itself, as expected. The second-most similar 
protein was phosphorylated EGFR (Tyr1068). Overall, the selections among the different 
measures were highly congruent. However, among the three threshold-cases, there were 
several cases where relevant HNSCC-relevant proteins were selected by the multivariate 
hypergeometric similarity measure, but not by others. These included well-known cancer-
related proteins like c-Myc [148], phosphorylated c-Jun [149], HER2 [150], and NF-kB 
[1], as well as proteins which have been implicated in HNSCC in recent studies, like 
INPP4B [151, 152] and ACC1  and AMPK [153]. Others highlighted only by the 
multivariate hypergeometric similarity measure in this case study were GSK3-alpha-beta 
[154], Ku80 [155], and TSC1 [156].  
 
Table 2.6: Top 20 rankings by similarity measures on head and neck cancer RPPA data, 




Pearson correlation Cosine similarity Mutual information 
1 EGFR EGFR EGFR EGFR 
2 EGFR_pY1068 EGFR_pY1068 EGFR_pY1068 EGFR_pY1068 
3 mTOR mTOR mTOR CD31 
4 p70S6K VHL VHL mTOR 
5 PDK1_pS241 PDK1_pS241 PDK1_pS241 VHL 
6 beta-Catenin HER2_pY1248 HER2_pY1248 p70S6K 
7 VHL Chk1_pS345 Chk1_pS345 PDK1_pS241 
8 E-Cadherin p70S6K p70S6K Akt 
9 AMPK_pT172 eEF2K eEF2K 14-3-3_epsilon 
10 eEF2K Tuberin Tuberin SF2 
11 Ku80 E-Cadherin E-Cadherin PDK1 
12 Tuberin INPP4B INPP4B eEF2K 
13 eIF4G eIF4G eIF4G beta-Catenin 
14 HER2 beta-Catenin beta-Catenin PRDX1 
15 Chk1_pS345 Ku80 Ku80 Bax 
16 ACC_pS79 Dvl3 Dvl3 
Caspase-
7_cleavedD198 
17 p90RSK ERK2 ERK2 HER2_pY1248 
18 NF-kB-p65_pS536 p90RSK p90RSK E-Cadherin 
19 c-Jun_pS73 ACC1 ACC1 c-Met_pY1235 







2.5.3. Mass Spectrometry Imaging (Lipidomic) Data 
In the final set of results, the similarity measure was applied to the experimental 
MSI data. The top 12 m/z images selected by each measure are shown in Figure 2.11. All 
measures agree that the reference itself is the most similar (selection 1: m/z 889.6). 
Notably, the proposed similarity measure gives results which are qualitatively very 
similar to the reference m/z image. The Pearson correlation and mutual information 
results for three classes also closely resemble the reference m/z image, while the cosine 
similarity results for three classes include several noisy images without a clearly 
discernible pattern. Interestingly, the top 12 results selected by the proposed similarity  
 
Multivariate hypergeometric similarity 
measure (mean) 
 









Figure 2.11: The 12 most similar m/z images, as ranked by the four similarity measures. 
The multivariate hypergeometric similarity measure results are shown with the mean and 
kurtosis as combination functions. 
 
1. m/z  889.6 2. m/z  907.6 3. m/z  891.7 4. m/z  905.6 5. m/z  892.5 6. m/z  890.4
7. m/z  890.8 8. m/z  879.9 9. m/z  864.6 10. m/z  880.7 11. m/z  908.9 12. m/z  807.3
1. m/z  889.6 2. m/z  907.6 3. m/z  905.6 4. m/z  891.7 5. m/z  864.6 6. m/z  892.5
7. m/z  894.5 8. m/z  890.8 9. m/z  879.9 10. m/z  908.4 11. m/z  888.4 12. m/z  807.3
1. m/z  889.6 2. m/z  907.6 3. m/z  891.7 4. m/z  893.7 5. m/z  880.7 6. m/z  892.5
7. m/z  890.8 8. m/z  879.5 9. m/z  890.4 10. m/z  905.6 11. m/z  807.3 12. m/z  864.6
1. m/z  889.6 2. m/z  664.9 3. m/z  891.7 4. m/z  697.7 5. m/z  606.8 6. m/z  624.7
7. m/z  623.7 8. m/z  694.8 9. m/z  625.7 10. m/z  713.6 11. m/z  890.8 12. m/z  907.6
1. m/z  889.6 2. m/z  907.6 3. m/z  891.7 4. m/z  880.7 5. m/z  892.5 6. m/z  893.7
7. m/z  879.5 8. m/z  890.4 9. m/z  890.8 10. m/z  864.6 11. m/z  807.3 12. m/z  863.8
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measure using the mean and kurtosis as combination functions are not identical. 
Moreover, neither set of results overlaps completely with the results from Pearson 
correlation, mutual information, and cosine similarity. For example, the proposed 
similarity measure, using the mean as the combination function, selects m/z 908.9, which 
none of the others select. Similarly, m/z 894.5, another unique selection, is picked by the 
proposed similarity measure when using the kurtosis as the combination function. 
Examining the top n results is common when applying a similarity measure to a dataset, 
and these observations indicate that applying the proposed multivariate hypergeometric 
similarity measure can yield relevant and useful results. 
2.6. Discussion and Key Innovations 
This chapter describes the design, development, and testing of two similarity 
measures. The second, the multivariate hypergeometric similarity measure, is the main 
result. It enables the pairwise comparison of images and data vectors featuring any 
positive integer number of intensity levels. This is an extension of initial work on the 
hypergeometric similarity measure, which was restricted to binary data. Using synthetic 
datasets, the proposed multivariate measure was compared to Pearson correlation, cosine 
similarity and mutual information in terms of sample rankings, and identified several 
favorable properties of the proposed measure. Next, a method of piecewise 
approximation was developed to facilitate the application of this approach to large 
datasets. Piecewise approximation was tested at several different subsection sizes on 
synthetic data, and was observed to follow the trend of the exact score. Functions for 
combining subsection similarity scores found through piecewise approximation were 
empirically assessed using biological data. The proposed similarity measure was tested 
on two HNSCC datasets: gene expression microarray data and reverse phase protein array 
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(RPPA) data. The proposed similarity measure was also demonstrated to be effective in 
identifying qualitatively similar images in a lipidomics MSI dataset. Critically, for all 
datasets, it made relevant selections which were not identified by other similarity 
measures in their top selections. 
The results of this study highlight several avenues for further research on the 
multivariate hypergeometric similarity measure. For instance, this approach is defined for 
any positive integer number of classes, but the results in this study have considered only 
three classes. Three classes were chosen both for simplicity in examining similarity 
measure properties and to highlight the difference between the binary case and the multi-
class case. Future research can assess the effect of increasing the number of classes. 
However, as previously noted, the generation of the isomarginal family becomes 
increasingly demanding as the number of classes increases [121-124]. Additionally, 
alternative definitions of the statistic S(k) will be explored. Here, I chose S(k) as the set of 
diagonal elements of the contingency table. In the future, it may be desirable to include 
sub- and super-diagonal terms when larger numbers of classes are considered. The 
selection of the appropriate number of classes – and of appropriate thresholds for 
separating classes – is another issue of interest. In this study, several percentile-based 
thresholds between classes were compared for the gene and protein expression datasets. 
From the perspective of practical biomedical applications, choices of thresholds for a 
particular dataset may be based on examination of descriptive data statistics, or by 
applying selected tests as a preliminary step [157]. The selection of functions for 
aggregating subsection scores obtained from piecewise approximation is another area for 
further study. Six functions were tested in this study, and many additional functions could 
50 
 
be tested. Interestingly, the set of top selections using the mean and kurtosis were not 
identical, indicating that it may also be useful to consider which combination functions 
may be complimentary.  
The Key Innovations of this chapter are: 
 Development of binary hypergeometric similarity measure using Fisher’s exact 
test 
 Development of multivariate hypergeometric similarity measure using the Fisher-
Freeman-Halton test 
 Development of a piecewise approximation algorithm to facilitate application of 
the multivariate hypergeometric similarity measure to high-dimensional data 
vectors 
 Implementation on two HNSCC (transcriptomic and proteomic) and one non-
HNSCC (MSI, metabolomic / lipidomic) datasets indicates that the proposed 
multivariate hypergeometric similarity measure makes relevant selections not 








DETECT-TLC: EXPLORATORY DATA MINING FOR 
METABOLOMICS  
3.1. Data Acquisition for Metabolomics 
 Metabolomics offers a perspective of the small molecules, including lipids, within 
an organism or patient [158, 159]. Compared to other –omics levels, the “chemical 
fingerprint” measured through metabolomics is highly dynamic, and has been shown to 
be a promising direction for the diagnosis and monitoring of disease [160, 161]. In 
HNSCC in particular, metabolomics approaches are demonstrating promising results for 
disease detection and early diagnosis [34-36] 
The key data acquisition methodologies used in metabolomics are 
1
H NMR and 
mass spectrometry. Mass spectrometry is used both alone and coupled to liquid (LC) and 
gas (GC) chromatography (LC-MS and GS-MS, respectively) [162, 163]. The reason for 
this coupling is because the chromatography step staggers the input sample flow to the 
mass spectrometer according to size, charge, or other properties, thereby generating 
sparser and easier-to-interpret mass spectra.  
3.1.1. Coupling Thin Layer Chromatography with Mass Spectrometry Imaging 
While LC and GC both return 1D data – i.e., spectra with intensities on the 
vertical axis and retention time on the horizontal axis – thin layer chromatography (TLC) 
is a 2D chromatographic separation process. Figure 3.1 shows how separated mixture 
components appear as spots on a TLC plate. TLC is a commonly used technique in 




Figure 3.1: Optical image of a TLC plate. Image courtesy of Fernández Lab at Georgia 
Institute of Technology.  
 
simplicity and speed [164]. In metabolomics, TLC alone has been applied to study 
bacteria [165, 166], but it is frequently combined with mass spectrometry analysis.  
Due to the 2D nature of TLC, it can be coupled with mass spectrometry either by 
assessing an individual spot using conventional mass spectrometry, or by interrogating 
the entire TLC plate through MSI [167-170]. MSI analysis of TLC plates has been 
performed using different mass spectrometry ionization approaches, including including 
matrix assisted laser desorption ionization (MALDI) [171] and desorption electrospray 
ionization (DESI) [172, 173].  
The advantage of TLC-MSI coupling is the molecular-level resolution: instead of 
being restricted to spots visible on the TLC plate, the MSI datacube can describe 
thousands of measurable spots. Examining a TLC-MSI dataset is straightforward if the 
analyte of interest is known, but for exploratory data mining purposes, the volume of data 
presents a challenge. This provides an opportunity for knowledge-driven mining in terms 
of implicit similarity: the goal is to identify all m/z images containing regions similar to a 
TLC spot, regardless of its spatial location or orientation. Currently, the state-of-the-art is 
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manual inspection of the thousands of images in the MSI dataset to detect such images of 
interest, which is a substantial data processing bottleneck. This chapter presents the 
development, testing, and validation of DetectTLC, a software tool for automatically 
detecting m/z images containing regions similar to TLC spots.   
3.2. Development of Image Feature-Based Modeling Tool 
The hypothesis behind DetectTLC is that m/z images containing spot-like regions 
are distinguishable from other images on the basis of quantitative image features.  
DetectTLC utilizes a five-step image processing pipeline, culminating in the extraction of 
such features. In the first step, smoothing filters are used to remove background noise 
from the m/z images, and very sparse and noisy images are excluded based on pixel 
counts. In the second step, the continuous-intensity m/z images comprising the MSI 
dataset are converted into binary images. In the third step, morphological image 
processing operations are used to fill in small holes in the binary m/z images. In the 
fourth step, quantitative image features are extracted for each m/z image in the dataset, 
with the goal of associating more extreme feature values with m/z images which contain 
TLC spot-like regions. In the fifth and final step, the m/z images are ranked in terms of 
the quantitative image features and are visualized in the graphical user interface. 
Alternative combinations of these steps were compared in order to identify well-
performing pipelines. Each of these steps is discussed in detail in the following section.  
3.2.1. Image Processing Pipeline 
Step 1: Smoothing and Pixel-count Filters 
Median filtering was used to remove background noise. For the MSI datasets 
examined in this study, 5×5 and 7×7 median filters were compared, but the difference in 
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performance was small compared to the effects of other factors, so only results from 7×7 
filters are shown. Median filtered-results are also compared with un-filtered results. 
The pixel-count-based filter was useful for removing sparse and streak-filled 
images from consideration. It was observed that many DESI-MSI images were sparse or 
streak-filled. In different datasets, the necessity of performing this filtering step may 
vary, as few such images may exist. Typically, binary m/z images with fewer than 5 and 
more than 1500 non-zero pixels were removed from consideration. Results with and 
without this filtering step were compared. 
 
Step 2: Generating Binary Images 
Two different methods for generating binary images were compared in this study. 
The first is a manually-selected threshold: if any signal S was present at a pixel (x, y) in 
the original m/z image above the threshold value T (i.e., S(x, y) > T), the value of the pixel 
in the binary image B(x, y) = 1. Otherwise, B(x, y) = 0. Users may select the desired 
threshold through the Advanced Options menu of the DetectTLC interface, which also 
provides a visualization of the selected threshold with respect to the average spectrum of 
the dataset. The second technique is Otsu’s method, which selects the threshold at which 
the within-class variance of the pixels assigned to each label is minimized [174]. 
 
Step 3: Morphological Operations 
As shown in Figure 3.2, an m/z image may feature a spot-like region that is not 
solid, i.e., single pixels or clusters of a few pixels where no or low signal was detected 




Figure 3.2: Example of a TLC spot-like region in an m/z image. Note that the spot 
consists of both high- and low-intensity pixels.  
 
as a single spot-like region regardless. However, these discontinuities can influence the 
automated, image-feature based detection of spot-like regions. To address this issue, 
DetectTLC applies morphological image processing operations to the MSI dataset. 
Erosion and dilation are two basic morphological operators used in image processing. A 
structuring element of a particular shape – common shapes include disks, squares, and 
diamonds – is used to remove (in erosion) or add (in dilation) a layer of pixels from the 
image. The compound morphological operators of opening and closing are defined in 
terms of erosion and dilation: in opening, erosion is followed by dilation, and in closing, 
dilation is followed by erosion. In this study, we compared the performance of dilation 
and opening in generating homogenous spot-like regions: dilation fills in small holes in a 
single region and gaps between regions, while opening removes connections between 
separate regions.  
 
Step 4: Scoring Based on Quantitative Image Feature Values 
The performances of eight quantitative image features were investigated and 
compared in the development of DetectTLC. These included seven shape-based features: 
56 
 
area, compactness, convex area, eccentricity, extent, number of connected regions, and 
solidity; and one texture-based feature: entropy. Each of these features is described 
further in Table 3.1.   






A =  ∑     , where x 
represents pixels with a 
value of one in the binary 
image, and f is a 
neighborhood operation 
function. 
This feature is the weighted sum of pixels 
with a value of one in the binary image. 
Different spatial distributions of pixels are 
weighted. Images containing a spot-like 
region may have lower area values than 





 / A, where P is 
the perimeter of the non-
zero region and A is its 
area. 
 
Compactness is a regional descriptor 
defined as the ratio of an object’s squared 
perimeter to its area. Compactness is 
minimal for disk-shaped regions [115], so 
images with a spot-like region may be 
characterized by lower compactness values. 
Convex area 
(Ca) 
Ca = ∑  where x 
represents pixels which 




The convex area is the number of pixels 
inside the convex hull, which is the 
smallest convex polygon that contains the 
entire region of non-zero pixels. A smaller 
convex area implies a small, cohesive 
region of interest, so images containing a 
spot-like region may be characterized by 




Ec = Dc / Dv, where Dc is 
the distance from the 
center to the focus of the 
ellipse, and Dv is the 
distance from the center to 
a vertex. 
 
Eccentricity is calculated by fitting an 
ellipse to the region of interest, such that 
the ellipse and the region share the same 
second moments. The image feature is then 
the eccentricity of the fitted ellipse. For a 
circular region, eccentricity would be 0; for 
a line it would be 1. Images containing a 
spot-like region may be characterized by 
lower eccentricity values. 
 
Table 3.1 continued overleaf. 
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Table 3.1, continued 
Entropy (En) 
En = -∑          , i = 
0...1, where    represents 
the fraction of zero (i = 0) 
and non-zero (i = 1) pixels 
in the image. 
 
Entropy is a measure of randomness used 
to describe image texture. For binary 
images, entropy is defined in terms of the 
fractions of zero and non-zero pixels. The 
quantity is maximized when the fraction of 
each pixel type is equal, so images with 
larger spot-like regions may be 
characterized by higher entropy values. 
 
Extent (Ex) 
Ex = ∑  /  ∑ , where x 
represents pixels which 
are within the region, and 
B represents all pixels 
which are within the 
bounding box. 
Extent is defined in terms of the bounding 
box, which is the smallest rectangular 
region that completely encloses the region. 
Extent measures the proportion to which 
the region of interest fills the bounding 
box. Images with a spot-like region may be 






Re = E + H, where E is 
the Euler number and H is 
the number of holes. 
The number of connected components is 
related to the Euler number (E), a 
commonly used shape-based image feature. 
The Euler number is defined as the 
difference between the number of 
connected components and the number of 
holes (H). In an image with solid spot-like 
feature, ideally there would be no holes (Re 
= E), so the number of connected 
components was considered as a feature 
instead of Euler’s number. Images with 
several distinct spot-like regions may be 
characterized by higher values of Re. 
 
Solidity (S) 
S = A / Ca, where A is the 
image feature Area and 
Ca is the image feature 
Convex area. 
Solidity is a composite feature, defined in 
terms of Area and Convex Area. This 
image feature measures the fraction of 
pixels which are in both the convex hull 
and the region of interest. Images with a 
spot-like region may be characterized by 
higher values of S. 
 
3.2.2. Features of Graphical User Interface 
The user interface comprises four windows, with the main window shown in 




Figure 3.3: The main graphical user interface with the top 24 images containing spot-like 
regions are displayed. Data is first uploaded and (optionally) de-isotoped, following 
which the user may select from “Protocol 1” or “Protocol 2” for feature selection, or 
design their own processing pipeline through the “Advanced Options” tab. Spots with 
similar spatial distributions may be identified using the “Similarity Options”. Selected 
images and/or spectra may be exported using the “Export Options”. 
 
algorithms, and contains a control panel for accessing the “Load New Dataset“, 
“Advanced Options”, and “Similarity Options” menus. Algorithm results are displayed 
on the main graphical user interface (GUI), 24 m/z images at a time. After running a 
processing protocol, images are initially sorted based on a quantitative image feature-
based score. Within each window, they may be re-sorted by ascending m/z value for 
convenience. A scroll bar is used to scan though all images, which may also be visualized 
with alternate color schemes if desired. Additionally, the user can narrow the examined 
mass range for more targeted examination of images containing spot-like regions. The 
main user options in the DetectTLC GUI are described below.  
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Load New Dataset 
DetectTLC accommodates MSI data in Analyze 7.5 and mzXML format (with 
time and position information). It also accepts MSI data which have been imported into 
MATLAB and saved as matrices in ‘.mat’ files. Thus, other MSI data formats can also be 
used with DetectTLC if they are first imported into MATLAB. 
 
De-isotope data 
DetectTLC currently uses a basic de-isotoping algorithm in which the highest-
intensity m/z value in each 3 Da-window is retained. Each spectrum is de-isotoped 
individually, and the spectra are then re-assembled into a de-isotoped datacube. After de-
isotoping is performed, all further processing protocols will automatically be performed 
on the de-isotoped data. In order to return to the raw data (with no de-isotoping), it is 
necessary to re-load the data files. 
 
Visualization 
The main graphical user interface displays 24 m/z images at a time. The scroll bar 
at the bottom of the tool screen allows users to scroll through the dataset, showing m/z 
images 25-48, 49-72, etc. Whenever a processing protocol is implemented, the interface 
will show the top 24 m/z images according to that protocol, and the user can scroll 
through the rest of the ordered selections. Additionally, the user can select among three 





Pre-set automatic protocols 
Two automatic protocols are offered. The first, “Protocol 1: Larger spots”, uses 
entropy as the quantitative image feature for scoring. The second, “Protocol 2: Smaller 
spots”, uses compactness as the image feature. The default settings for filtering by 
intensity, filtering by non-zero pixels and median filtering are implemented in both of 
these protocols. 
 
Refresh current dataset 
By pressing the “Refresh dataset” button, the user can return the display to the 
original MSI data before any processing protocols (pre-set or via the advanced options) 
were applied. If the dataset had been de-isotoped, the de-isotoped data will be shown. 
 
Find m/z values 
This option displays all images corresponding to the user-input m/z range. Any 
processing steps that are called after the “Find m/z values” command will operate only on 
the images within that m/z range. To process the entire dataset, it is necessary to press the 
‘Refresh dataset’ button first. 
 
Ignore m/z values 
This feature can be used to select m/z images which are not of interest to the user 
(e.g., noisy images, or images with homogeneous signal intensity) and remove them from 
the current dataset view. The original MSI data can be retrieved by using the “Refresh 
dataset” option.  
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Sort by image feature value or m/z value 
As a default, the m/z images returned by any processing protocol are sorted by the 
quantitative image feature value. To facilitate review, the 24 images within an individual 
screen may also be sorted in order of ascending m/z value.  
 
Export (with or without average spectrum) 
Two different export utilities are available in DetectTLC: (1) Export Selected 
Images and (2) Export With Spectrum. In (1) Export Selected Images, the user can use 
the checkboxes below each m/z image to make selections, and then click the button 
labeled “Export Selected Images”. All selected images will be saved in ‘.fig’ format to 
the user-specified directory, and an ASCII file listing the selected m/z values will be 
created in the same directory. Multiple m/z images within one screen (24 images) can be 
exported simultaneously. In (2) Export With Spectrum, the user will instead click the 
button labeled “With Spectrum”. A new figure will appear, showing the selected m/z 
image. The user can use the drawing cursor to select a region of interest by drawing a line 
through the spot-like region or around it. After the region of interest is selected, a 
composite figure containing both the m/z image and the average spectrum in the region of 
interest (Figure 3.4) will be saved as a MATLAB ‘.fig’ file in the user-specified 
directory. Again, multiple m/z images (24 per screen) can be selected simultaneously. If 
multiple m/z images are selected, the process of manual region of interest selection will 
be repeated for each image, and an ASCII file listing the selected m/z values will be 




 Figure 3.4: Example of selected m/z image (m/z 140.1043) to draw a region of interest 
(ROI, outlined in white) and resulting average spectrum for selected pixels. 
 
Advanced Options GUI 
The Advanced Options GUI (Figure 3.5) provides users with more control over 
how the MSI data is processed and analyzed. Four different pre-processing control panels 
are available: (1) Generation of binary images; (2) Pixel-count filtering; (3) Median 
filtering; and (4) Image feature selection. 
 




In DetectTLC, morphological operations and image feature scores are computed 
on binary m/z images.  In the “Generation of binary images” control panel, the user has 
the option of using Otsu’s method (default) or manually selecting a threshold for 
generating binary m/z images. The success of the thresholding process is highly 
dependent on spectral signal-to-noise; it is valuable to identify genuine spots that may 
have low abundance, but that are still sufficiently above baseline noise. Manual threshold 
selection allows for the user’s knowledge of the spectral quality to be factored into the 
processing, but Otsu’s method for threshold selection provides a satisfactory approach 
without the need for user input. In the case studies presented here, manual threshold 
selection and Otsu’s method yielded comparable results across all other processing 
variables. The average spectrum across the MSI dataset is displayed below the 
thresholding panel in the GUI, and when the “Apply” button is clicked, the manually-
selected threshold is overlaid on the spectrum as a red line. 
The “Pixel-count filtering” control panel can be used to eliminate sparse images 
(i.e., m/z images with non-zero signal in very few pixels) and so-called streaky images 
(i.e., m/z images with high intensity signal in many pixels, but in a noisy, non-informative 
spatial pattern). In the MSI dataset analyzed in this paper, sparse images were generated 
as a result of the centroiding process. These images were eliminated by establishing a 
minimum of 5 pixels for a spot to be detected. Conversely, no more than 1500 pixels for 
a particular m/z could be present for a true spot, as the presence of that many pixels 
indicated streaks or widespread presence of a species across the entire TLC plate (e.g., an 
impurity in the DESI solvent). For general use, a histogram showing the distribution of 
m/z images with different numbers of non-zero pixels is displayed. The user can refer to 
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this histogram to select the upper and lower thresholds for pixel-count filtering. When the 
“Apply” button is clicked, all m/z images containing a number of non-zero pixels above 
the upper threshold or below the lower threshold are discarded from the dataset. The 
default setting is to discard images with fewer than 5 non-zero pixels and with more than 
1500 non-zero pixels. 
In the “Median filtering of m/z images” panel, the user can select the size of the 
two-dimensional median filter applied to remove “salt-and-pepper” background noise 
from the m/z images. The default setting is a 5×5 median filter. If no median filtering is 
desired, the filter size should be set to 0×0. 
The fourth and final panel allows the user to select from among the eight image 
features investigated in this paper: area, compactness, convex area, eccentricity, entropy, 
extent, number of connected regions, and solidity. The m/z images remaining after the 
filtering steps, sorted according to the selected image feature, will be displayed in the 
main GUI. Selection of the image feature of interest is independent of the three pre-
processing options. It is not necessary to perform any pre-processing before applying the 
image feature-based sorting – the default settings of Otsu’s method, < 5, > 1500 pixel-
count filtering, and 5×5 median filtering will be applied. The three pre-processing steps 
can also be applied individually or in any combination prior to selecting an image feature. 
 
Similarity Assessment 
Multiple protocols for performing similarity analysis are available in DetectTLC. 
The most basic method, which is implemented by selecting any m/z image via its  
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Figure 3.6: Advanced Similarity Options GUI in DetectTLC. The binary template 
corresponding to the selected m/z image for m/z 140 is shown as an example. 
 
checkbox and clicking the “Find Similar” button, will return the most similar m/z images 
within the same dataset, as ranked by the binary hypergeometric similarity measure 
(described in Chapter 2). Alternatively, by clicking the “Advanced Similarity” button, the 
Advanced Similarity Options window will open, as shown in Figure 3.6.   
The Advanced Similarity Options window provides three methods for managing 
the region of interest (ROI) for similarity assessment. These are: (1) Create and save a 
new ROI template (may then be used with the same or another dataset, i.e., “inter-
dataset”); (2) Import an existing ROI template (may be from the same or another dataset, 
i.e., “inter-dataset”); (3) Create and implement an ROI template on the current dataset 
(i.e., “intra-dataset”). These options are described further as follows. 
The first option, “Save ROI (inter-dataset)” enables the user to draw a binary ROI 
template and save it for later use, with the same or another MSI dataset having the same 
spatial dimensions. If the checkbox of any m/z image was selected in the main GUI, that 
m/z image will be provided as the guide for drawing the binary template. If not, the 
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average image across the loaded dataset will be provided. Once the template is drawn, the 
user may save it to a selected filename and directory. If a particular m/z image is used as 
the template basis, three variables are saved: the binary ROI, the m/z vector from current 
dataset, and the peak height of selected m/z in the current average spectrum. When the 
template is imported later, this data will be used to draw a spectrum of similar peaks. If 
the average m/z image is used as the template basis, only the binary ROI is saved. 
In the second option, “Import ROI (inter-dataset)”, a previously drawn ROI can 
be loaded. In order to use this ROI for similarity assessment, it must have the same 
spatial dimensions as the currently loaded dataset. Some variations in spatial dimensions 
can be handled by DetectTLC. These are: 
1. Template image is rotated 90 degrees with respect to current dataset. DetectTLC 
will rotate the template so that the dimensions match. 
2. Template image has one extra row and/or column. DetectTLC will delete the first 
row and/or column from the dataset. 
3. Template image is rotated 90 degrees and has an extra row and/or column.  
Before any of these actions are taken, DetectTLC will notify the user that the 
spatial dimensions of the current dataset and selected template do not match. If the 
mismatch falls into any of these three categories, DetectTLC will prompt as to whether 
the template should be automatically adjusted. If the mismatch does not fall into these 
three categories, DetectTLC will prompt the user to load a different template for use with 
the current dataset. 
In the third option, “Draw template (intra-dataset)”, the user can draw a template 
which will immediately be used for similarity assessment on the currently loaded dataset, 
67 
 
and which will not be saved. This differs from basic “Find Similar” option in that the user 
may select which similarity metric to use, and the spectrum of most similar peaks may be 
plotted. 
After a template is available (either through the Import or Draw options), the 
median filter, pixel-count filter, “Choose similarity measure,” and “Plot spectrum of most 
similar” panels become visible. The median filter and pixel-count filter options are as 
described previously. The user may select between two similarity measures: Pearson 
correlation or the hypergeometric similarity measure. As discussed in Chapter 2, analyses 
on MSI and other types of high-dimensional data have indicated that these two similarity 
measures tend to yield relevant but complementary (i.e., including non-overlapping, 
unique selections) top ranked results [175, 176]. Once the “Select” button is pressed, 
similarity assessment will proceed using the selected measure, and the m/z values in the 
current dataset will be sorted in the main GUI according to their similarity to the 
template. After similarity assessment has completed, the user may plot a spectrum of 
most similar m/z values by choosing the number to plot in the “Plot spectrum of most 
similar” panel. If the imported template was based on a particular m/z value, that m/z 
value (the precursor peak, in precursor-product analysis) will be indicated in red on the 
spectrum, and the similar peaks from the current dataset will be plotted in black. 
Otherwise, all peaks will be plotted in black. 
3.3. Case Studies 
The datasets used for the case studies are related to prebiotically-relevant abiotic 
synthesis of nucleic acids such as DNA and RNA. While these datasets are not linked to 
HNSCC, the advantage is that they are less complex mixtures than eukaryotic cell 
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lysates. Thus, they provide test cases for DetectTLC that have comparatively less 
chemical noise and are easier to interpret, thereby facilitating the testing and validation of 
the tool.  
Three datasets were investigated. The first and second both involved reaction 
products that are part of the synthesis of pyrazin-2-one (PZO). The two datasets were 
generated by using two different solvent systems (A and B). PZO-A was used in the first 
case study, Pipeline Comparison, and PZO-A and PZO-B were investigated in the second 
case study, TLC Spot Detection. The third dataset, which was utilized in the Parent-
Fragment Ion Detection case study, used the reaction synthesis mixture for 2-
aminopyrazine (APZ). All datasets were DESI-MSI. The full details of the experimental 
data acquisition process are described in [177].  
3.3.1. Pipeline Comparison 
Considering the two thresholding methods, two morphological operators, two 
median filter options (none and 7×7), two pixel-count filter options (none and excluding 
< 5, > 1500), and eight image features, a total of 128 alternative processing pipelines are 
possible. These were compared for the PZO MSI dataset. Each pipeline was assessed by 
the number of images in the top 40 rankings which contained true spot-like regions, as 
determined by manual inspection and verification of selected spots by collaborators in the 
Fernández lab. The full results of this comparison are shown in Table 3.2.  
For this MSI dataset, the best results were returned by the analysis pipeline 
consisting of (1) Otsu’s threshold, (2) morphological opening, (3) application of a 7×7 
median filter, and (4) removal of images with < 5 and > 1500 non-zero pixels. For all of 




Table 3.2: Performance comparison of all 128 alternative processing pipelines in 





Figure 3.7: Example of m/z images featuring larger TLC spot-like regions. The top 40 
selections are shown for the analysis pipeline consisting of (1) Otsu’s method for 
generating binary images, (2) morphological opening, (3) 7×7 median filtering, (4) 
removal of images with < 5 and > 1500 non-zero pixels, and (5) entropy image feature. 
 
 
Figure 3.8: Example of m/z images featuring smaller TLC spot-like regions. The top 40 
selections are shown for the analysis pipeline consisting of (1) Otsu’s method for 
generating binary images, (2) morphological opening, (3) 7×7 median filtering, (4) 






like regions. The difference among the feature measures is most clearly demonstrated by 
the variety and size of the spots identified, as illustrated to an extent in Figures 3.7-3.8.  
To further investigate these differences, the overlap among the top 40 rankings 
between each feature pair is shown in Table 3.3. This comparison confirms qualitative 
observations: image features which returned m/z images with smaller spot-like regions, 
such as compactness and convex area, had similar top 40 lists (e.g., 34/40 in common). 
Meanwhile, entropy, which returned m/z images with larger spot-like regions, and 
compactness had very different lists (e.g., 11/40 in common). Importantly, none of the 
image features were completely redundant in terms of their top 40 rankings. Image 
feature pairs which highlighted similar types (e.g. smaller or larger) of spot-like regions 
still returned unique m/z images. For example, entropy and extent both tended to  
 
Table 3.3: Pairwise comparison of m/z images selected as the top 40 selections by 







highlight larger spot-like regions, but only 20/40 of their top-ranked images were in 
common. Thus, examining both of their top-ranked lists would be helpful during analysis, 
compared to considering only one image feature.  
 
3.3.2. TLC Spot Detection 
This case study demonstrates the application of DetectTLC in exploratory data 
mining through the PZO-A and PZO-B datasets. 
 
DetectTLC Identifies Known Reaction Mixture Components 
Three major products of the PZO synthesis process have previously been 
identified, and their chemical structures are known. These molecules are indicated in 
Figure 3.9(b). The TLC-MSI dataset was analyzed using DetectTLC. The top 20 results 
included images corresponding to the known products in terms of m/z and spatial 
location, as shown in Figure 3.9(c-d).  
 
 
Figure 3.9: (a) Fluorescence image of a developed high-performance TLC (HPTLC) plate 
with the area imaged through DESI-MSI outlined in green (b) Known products of the 
PZO reaction, with numbers indicating the spatial location of each product in the 
fluorescence and MS images (c) Selected ion images acquired by DESI-MSI of reaction 




DetectTLC Can Help to Identify Relevant Components through Untargeted Analysis 
When the PZO reaction mixture was analyzed using solvent system B, an intense 
fluorescent spot was observed that had not been seen using solvent system A, as shown in 
Figure 3.10(a). Processing the PZO-B dataset with DetectTLC yielded an ion image (m/z 
167.0353) in which the spot was co-localized with that of the fluorescent image, as 
shown in Figure 3.10(c). This image was the 13
th
 generated by DetectTLC, and appeared 
on the first page of results in the main GUI. Combining the DetectTLC-supplied m/z 
value with knowledge of reaction chemistry, my collaborators in the Fernández lab were 
able to tentatively identify this spot as 3,5(6)-dimethyl-4-oxoethyl-2-oxo-pyrazin-4-ium, 
a plausible reaction side-product of PZO synthesis.  
 
Figure 3.10: (a) Fluorescence image of a developed high-performance TLC (HPTLC) 
plate of the PZO reaction mixture, as separated by solvent system B. The green box 
indicates the area imaged using DESI-MSI, and Spot 4 indicates the unknown signal. (b) 
The manually plotted image of m/z 167.0353 and (c) the DetectTLC image identifying 






3.3.3. Parent-Fragment Ion Detection 
The third and final case study applies the similarity assessment capabilities of 
DetectTLC to assist in structural identification of detected ions. In order to identify ions 
detected through mass spectrometry, it is necessary to obtain fragmentation data from 
high-energy ionization. In a typical tandem mass spectrometry (MS/MS) analysis, a 
precursor (parent) ion is selected for fragmentation. In MSI, selecting and fragmenting 
individual parent ions while maintaining high imaging throughput is challenging. A 
solution is to instead alternate between high- and low-energy scans while imaging, 
enabling both parent and fragment ions to be detected during a single experiment. This 
results in two datasets of equal or almost equal spatial dimensions, one consisting of 
parent ions, and another of fragment ions. DetectTLC utilizes spatial similarity measures 
to match potential fragments with parents. 
This process is performed by allowing the user to select a parent ion of interest 
using the ‘Advanced Similarity’ GUI, and then identifying the most similar images in the 
fragment ion dataset. The intact parent ion of interest was 5(2-hydroxyethyl)-2-
aminopyrazine (m/z 140.0817), a predicted side-product of the APZ reaction. The image 
corresponding to m/z 140.1 was first identified by DetectTLC from the low collision-
energy dataset, as previously shown in Figure 3.6, and was used to create a template of 
the spot’s location. Figures 3.11 and 3.12 show the results of the similarity assessment 
process, using Pearson correlation and the hypergeometric similarity measure, 
respectively. Both measures returned the same top 9 ranked ions, but sorted in different 
orders. Two of the top-ranked ions (m/z 122.0714 and 78.0345) were assigned to H2O 
and CH6N2O losses from the parent ion, respectively. This observed fragmentation 
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pattern supports the structural assignment of 5(2-hydroxyethyl)-2-aminopyrazine to ions 
at m/z 140.0817. 
In order to validate the fragment ions selected by DetectTLC, they were compared 
to liquid chromatography-tandem MS (LC-MS/MS) analysis performed on the parent ion.  
 
 
Figure 3.11: (top) The most similar fragment ion images observed when Pearson 
correlation was applied using the image of the precursor ion (m/z 140.1) as a reference. 
(bottom)  The fragmentation mass spectrum showing the top 10 most similar m/z values 
(reference m/z indicated by dashed red line). DetectTLC automatically generates both of 





Figure 3.12: (top) The most similar fragment ion images observed when the 
hypergeometric similarity was applied using the image of the precursor ion (m/z 140.1) as 
a reference. (bottom)  The fragmentation mass spectrum showing the top 10 most similar 
m/z values (reference m/z indicated by dashed red line). DetectTLC automatically 
generates both of these figures during similarity analysis. 
 
These results are shown in Figure 3.13. Three of the ions, at m/z 78.0, 122.1, and 140.1, 
were identified in both datasets. The LC-MS/MS experiment also identified four other 
fragment ions which were not selected by DetectTLC: m/z 95.1, 105.0, 109.1, and 110.1. 




Figure 3.13: Comparison of LC-MS/MS analysis of selected APZ reaction products and 
the manually-selected ion images from low- and high-energy scans DESI-MSI. 
DetectTLC similarity matching was performed using m/z 140.1 as a template, and the 
high-energy ion images with red borders were in the top 8 outputs of DetectTLC. Figure 
courtesy of Fernández lab.  
 
them (m/z 95.1, 105.0, and 109.1) had very low contrast between the TLC spot and the 
background. The deisotoping protocol was also found to be a factor in filtering out these 
relevant images; follow-up experiments (not shown) with smaller windows for 
deisotoping led to the selection of m/z 109.1 and 110.1 among the top 16 results.  
3.4. Applications to HNSCC Research 
DetectTLC is a general tool capable of processing TLC-MSI data from different 
biological contexts, including HNSCC. As previously noted, metabolomic research 
78 
 
through mass spectrometry in HNSCC is gaining momentum [35, 36]. In addition, TLC 
has been applied in HNSCC lipidomics research in several recent publications. For 
example, Gu and colleagues used TLC to separate and visualize lipids from five HNSCC 
cell lines in order to determine the mechanism by which RRR-α-tocopheryl succinate, a 
vitamin E analogue, induces apoptosis [178]. Yang and colleagues used TLC to track the 
effects of deguelin, which has been shown to have chemopreventive effects against other 
cancers, on HNSCC via the pro-apoptotic sphingolipid ceramide [179]. Thus, as research 
into metabolomics continues to grow, TLC-MSI analysis can help to uncover relevant 
metabolite- and lipid-centric patterns in HNSCC. DetectTLC can accelerate these 
experiments by removing the bottleneck of manual data processing.  
3.5. Discussion and Key Innovations 
In this chapter, I have described the design, development, and validation of 
DetectTLC, a software tool for accelerating metabolomics research through coupled 
TLC-MSI analysis. The previous state-of-the-art in assessing TLC-MSI datasets was 
manual inspection of the data to search for m/z images with TLC spot-like regions. 
DetectTLC automates this process, thereby removing a significant bottleneck to TLC-
MSI experiments. While the TLC-MSI datasets tested during its development are related 
to prebiotic chemistry, DetectTLC is a general system that can be applied to 
metabolomics research in many different contexts, including HNSCC.  
The utility of DetectTLC has been validated in the second and third case studies. 
First, it was demonstrated that DetectTLC is capable of automatically detecting spots 
corresponding to both expected and unexpected reaction mixture components. Second, it 
was demonstrated that DetectTLC can assist in structural identification of ions of interest 
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when multi-modal MSI is performed. During these validation experiments, some 
limitations of the current algorithms were also identified. Future versions of DetectTLC 
can incorporate image processing algorithms for the elimination of noisy background 
signals. They can also incorporate more sophisticated methods for deisotoping MSI data, 
in order to avoid inadvertent filtering of relevant m/z images in favor of neighboring 
high-intensity noisy images.  
DetectTLC was developed and implemented in MATLAB. To enable widespread 
use of the tool, an executable (.exe) version of the tool has been generated. The tool will 
soon be freely deployed to the community via the website of Bio-MIBLAB at Georgia 
Institute of Technology.  
The work described in this chapter was performed in collaboration with Dr. May 
D. Wang, Dr. Facundo M. Fernández and Dr. Rachel (Bennett) Stryffeler. Dr. Stryffeler 
performed MSI data acquisition and LC-MS/MS validation, while I implemented the 
DetectTLC tool and performed software-side experiments. The project idea and the 
design of DetectTLC tool capabilities and features were jointly developed.  
The Key Innovations of this chapter are: 
 Development of the first analytical pipelines using quantitative image features for 
identifying m/z images containing spot-like regions in MSI data 
 Design, implementation, and validation of the first software tool, DetectTLC, for 
enabling and accelerating TLC-MSI studies in metabolomics by automatically 






SUPERVISED LEARNING MODELS FOR PATHOLOGICAL 
STAGE USING PROTEOMIC AND TRANSCRIPTOMIC DATA 
4.1 HNSCC Disease Stage and Outcomes 
The stage at which HNSCC is detected is important to therapeutic outcomes; 
patients with early stage (I and II) cancer have between 60-95% chance of successful 
local treatment, while those with advanced stage cancer are at high risk for recurrence or 
metastatic disease [37]. Greater knowledge of the molecular characteristics of different 
stages can provide insight into the mechanisms of HNSCC progression, and may help in 
identifying more effective therapeutic targets and strategies for treatment.  
Previous research studies have analyzed gene expression, proteomic, and 
metabolomic data individually for studying differences between HNSCC stages, with 
mixed results. For example, three transcriptomic studies have related selected genes and 
gene signatures to different HNSCC stages [40, 45, 46], while two other transcriptomic 
studies did not find any discriminatory genes [41, 43]. A recent proteomic study using 
SELDI-TOF mass spectrometry data identified 11 m/z values differentially expressed 
between early- and late-stage oral SCC, but a satisfactory predictive model could not be 
developed [42]. Another recent study, using MALDI-TOF mass spectrometry data, 
identified several peaks that tended to correlate with clinical disease progression; 
however, no predictive model was developed [44]. A metabolomic study using 
1
H NMR 
data identified several metabolite markers that discriminated between early and advanced 
stage HNSCC samples [34]. Additional bioinformatics studies – and in particular, the 
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development of predictive models that harness multiple data types – may help to gain 
additional insight into the differences between early and advanced HNSCC.  
In this chapter, I investigated how quantitative functional proteomics, via reverse 
phase protein array (RPPA) data, can be used to develop predictive models for HNSCC 
stage. RPPA data is acquired by probing a sample with antibodies against specific 
proteins with regard to their activation states. With respect to HNSCC, RPPA data has 
been used to identify differentially expressed proteins between cancer and normal 
samples [180] and to identify proteins affected by the presence of an anti-invasion 
compound in nasopharyngeal carcinoma [181]. RPPA data has been applied to build 
predictive models for several other cancer types. Recent examples include for prognosis 
[182], drug response [183], and risk of recurrence [184] in breast cancer; for treatment 
response in ovarian cancer [185]; and for drug sensitivity in non-small-cell lung cancer 
[186].  
In addition, I expanded upon previous efforts by developing predictive models for 
the same patient set using RNAseq data, and performing integrated analysis of RPPA and 
RNAseq data through functional assessment and ensemble model development. The goal 
of this investigation is to develop a set of improved predictive models, and thereby gather 
additional insight into HNSCC progression across multiple biological scales.  
4.2 Protein and Gene Expression Datasets 
RPPA data for HNSCC was downloaded from The Cancer Proteome Atlas 
(TCPA)  [126] at http://bioinformatics.mdanderson.org/main/TCPA:Overview. This 
dataset consists of 212 patient samples and measures the response to 187 antibodies. 
TCPA provides a proteomic complement to The Cancer Genome Atlas (TCGA) [187] at 
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http://cancergenome.nih.gov/, where clinical, transcriptomic, and genomic data for the 
same patients are available. RNAseq data (Version 2) for HNSCC was downloaded from 
TCGA. Data was available for 210 of the same patients.  
The downloaded RPPA data had been normalized and protein expression had 
been quantified using the “Supercurve Fitting” method. The details of these pre-
processing steps are described in [126, 188]. In TCPA, antibodies are grouped into three 
classes: “validated”, “under evaluation”, and “use with caution.” To perform a more 
conservative analysis, only those proteins with antibodies described as “validated” in 
both [126, 188] were utilized in this study. 113 proteins were considered for further 
analysis. In TCGA, RNAseq (Version 2) data has been aligned using MapSplice and 
quantified using RSEM [189, 190]. This dataset describes 20,531 genes. The un-
normalized data was used for differential expression analysis and the normalized data 
was used for classification. 
The clinical data for the 212 patients was downloaded from TCGA. Pathological 
stage information was used to divide the RPPA and RNAseq datasets into two groups: 
patients with early stage (stage I and II) cancer, and patients with advanced stage (stage 
III, IVA, IVB) cancer. Pathological state was unavailable for 12 patients, so clinical stage 
was substituted. One patient for whom the pathological stage was unavailable and the 
clinical stage was IVC was not considered, because unlike the other advanced cases, 
stage IVC involves metastatic disease. For RPPA, the early stage group contained 50 
patients, and the advanced stage group contained 161 patients. The two patients for 




4.3. Model Development 
 
 
Figure 4.1:  The nested cross-validation framework used in this study. The outer split was 
repeated n = 3 times, and the inner 10-fold cross-validation was repeated m = 5 times. 
 
Classification Methods 
Four individual binary classification methods and two ensemble classification 
methods were tested: k-nearest neighbors (KNN), support vector machine (SVM), naïve 
Bayes, decision tree, Adaboost, and bagging / Random Forests. Optimal parameters for 
each model were selected via nested cross-validation and grid search. Table I lists the 
range of parameters tested for each model, and Figure 4.1 describes the 3×5×10 nested 
cross-validation scheme. Optimization was performed with respect to the Matthews 
correlation coefficient (MCC). The area under the ROC curve (AUC) is also reported for 
the model having the maximum mean MCC. Analyses were performed using MATLAB 






Table 4.1: Classification model parameters examined via nested cross-validation 
Classification Method Parameters Set of values 
KNN Number of neighbors (K)   [                    ] 
SVM Kernel 
Soft margin cost (C) 
  for GBRF 
Kernels: linear, Gaussian radial 
basis function (GRBF) 
C   2m, m   [-1,0,1] 
  2m, m   [-1,0,1] 
Naïve Bayes Prior distribution Distributions: normal, kernel 
Decision Tree Splitting criterion Criteria: Gini diversity index (GDI), 
Twoing rule, Maximum deviance 
reduction (MDR) 
Adaboost Number of trees (N)    [25,50,100] 
Bagging / Random 
Forests 
Proportion (m) of all 
variables (p) to retain 






  ] 
 
Feature Selection 
Three alternative feature selection methods were tested: two filter approaches and 
one wrapper approach.  
The first filter method was based on differential expression. For RPPA data, the 
Wilcoxon rank-sum test was applied to identify proteins with significantly different 
expression between the early and advanced stage groups. Multiple testing corrections 
were applied by calculating the FDR for each protein, using the method of Benjamini and 
Hochberg through the R package p.adjust. To obtain a less conservative initial feature set, 
clinical stage was used to obtain a differentially expressed protein list. This yielded 11 
proteins with FDR values ≤ 0.05, including the five proteins found when only 
pathological stage was used. A comprehensive examination of this feature space was 
performed by considering alternative classification models for every combination of the 
11 features, i.e., ∑ (  
 
)            feature sets were considered. For RNAseq data, 
differential expression analysis was performed using two alternative tools, edgeR and 
EBSeq, of which the latter uses Bayesian methods [191, 192]. For a threshold of  
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FDR ≤ 0.05, edgeR identified 495 genes and EBSeq found 267 genes. These two lists had 
108 genes in common. Due to the large number of differentially expressed genes 
identified by each method, comprehensive investigation of the feature space was not 
possible. Instead, model performances were compared across four feature sets: each 
differential expression result individually, the 108 common genes, and the 654 genes in 
the union of the selections of both methods.  
The second filter method was mRMR (minimum redundancy maximum 
relevance), implemented using the FEAST toolbox [193-195]. The performance of each 
model was optimized for up to the top 50 features. The RNAseq data contained 1,414,819 
unique count values, and the vast majority of values were observed only once. Due to this 
high dynamic range and memory limitations, the count values of the unscaled RNAseq 
data were binned prior to performing mRMR. The number of binned levels was chosen to 
balance performance and computational cost; 30,000 binned levels were the best 
alternative given the available computational resources.   
In the wrapper approach, sequential forward feature selection (SFS) was 
performed. Model performance was optimized for up to the top 20 features. Due to the 
large number of genes in the RNAseq data, SFS was performed only after initial filtering 
based on differential expression. The input to SFS was the 654 genes found to be 
differentially expressed by edgeR and EBSeq in combination.   
 
Data Scaling 
Due to the high dynamic range of features in RNAseq data, two data scaling 
methods were tested. In the first – denoted scaled (1) – each feature was scaled by 
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dividing by the maximum value observed for that feature across any sample. In the 
second – denoted scaled (2) – each feature was scaled by subtracting its mean and 
dividing by its standard deviation, as suggested in [196]. The predictive modeling results 
for RNAseq with SFS are from unscaled data. For the differential expression and mRMR 
feature selection techniques, the best result among the two alternative scaling choices and 
unscaled data is shown.  
 
Integrated Analysis 
One of the fundamental goals of systems biology is to integrate information from 
multiple levels of biological complexity in order to increase actionable biological and 
clinical knowledge. However, this is a very challenging task. Several studies have 
demonstrated that mRNA and protein expression levels generally exhibit only moderate 
linear correlation; that is, mRNA expression may predict protein expression to a partial 
extent, but protein expression is also influenced by regulation at the post-transcriptional 
and post-translational levels [197-200]. Thus, models developed by integrating mRNA 
and protein features in some manner may potentially show improved performance over 
models using individual data types only. In a recent review, Haider and Pal discussed 
eight frameworks for performing integrated analysis of transcriptomic and proteomic 
data: union of data types, comparison of functional contexts, topological network 
analysis, merging datasets in individual domains, missing value estimation, multiple 
regression analysis, clustering, and dynamic modeling [201]. Due to the constraints of the 
available data, the techniques of merging datasets in individual domains, missing value 
estimation, multiple regression analysis, and dynamic modeling are not possible. In this 
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chapter, I examine model development based on the first two remaining methods: 
combination of the two data types and the results of functional assessment.  
In the first case, RPPA and scaled RNAseq data were naively combined into a 
composite dataset. One dataset contained 221 features (113 RPPA and the 108 common 
RNAseq features) and the other contained 767 features (113 RPPA and the 654 union 
RNAseq features). SVM, KNN, and decision tree models with SFS were constructed 
using nested CV, with a maximum of 20 features. The better result among the two 
RNAseq scaling methods is reported.  
In the second case, functional analysis of the genes corresponding to RNAseq and 
RPPA features in the best-performing models was performed using DAVID [202, 203] 
and the Reactome Analysis Tool [204]. I hypothesized that, if an ensemble of these 
models was created, individual models representing different functional categories would 
yield better-performing ensembles. This was tested by systematically evaluating all 
possible ensembles from nine SFS models: SVM, KNN, naïve Bayes, decision tree, and 
Adaboost using RPPA data, and SVM, KNN, decision tree, and Adaboost using RNAseq 
data. Ensemble decisions followed a majority voting scheme, and mean MCC values 
were compared across 100 repetitions of 10-fold CV.  
4.4. Model Performance 
4.4.1. Individual Data Types 
Table 4.2 shows the predictive model performance of the six classifiers on the 
RPPA data. In general, performance is moderate, with several models achieving mean 
MCC values greater than 0.4 and AUC values greater than 0.7. The best performing  
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Table 4.2: Performance evaluation of alternative predictive models across feature 
selection methods for RPPA data 
Classification 
Method 
 Rank-Sum Test mRMR SFS 
  MCC AUC MCC AUC MCC AUC 
SVM  0.43±0.15 0.75±0.11 0.37±0.21 0.74±0.08 0.54±0.21 0.77±0.06 
Naïve Bayes  0.32±0.18 0.71±0.09 0.33±0.13 0.71±0.13 0.47±0.19 0.65±0.12 
Decision Tree  0.16±0.17 0.64±0.13 0.12±0.27 0.62±0.11 0.40±0.20 0.68±0.11 
KNN  0.35±0.28 0.74±0.13 0.28±0.13 0.77±0.09 0.46±0.22 0.73±0.11 
Adaboost  0.11±0.24 0.71±0.11 0.25±0.34 0.71±0.14 0.45±0.13 0.71±0.11 
Random 
Forests 
 MCC AUC 
 0.04±0.16 0.65±0.10 
 
RPPA model was SVM with SFS feature selection. The SVM models outperformed the 
other classifiers for all feature selection methods on the RPPA dataset, and the SFS 
models outperformed the other feature selection methods for all classifiers. The naïve 
Bayes and KNN models were the next best in performance, while the decision tree 
models did not perform as well. The two ensemble classifiers showed markedly different 
performance. For mRMR and SFS, Adaboost outperformed the decision tree models, 
although it did not perform as well as the other individual classifiers. The Random 
Forests classifier gave surprisingly poor performance for the RPPA data, with an MCC 
value close to zero.  
Table 4.3 shows the predictive model performance of five classifiers on the 
RNAseq data. The best RNAseq models, which achieve mean MCC values greater than 
0.6, outperform the best RPPA models. Again, the SFS models outperformed the other 
feature selection methods for all classifiers. The highest performing RNAseq model was 
KNN with SFS; the Adaboost and SVM models with SFS performed almost as well in 
terms of MCC, though the SVM AUC value was non-informative. The Random Forests 
model for RNAseq data showed better mean performance than that for RPPA data, but it 




Table 4.3: Performance evaluation of alternative predictive models across feature 







  MCC AUC MCC AUC MCC AUC 
SVM  0.52±0.27 0.91±0.11 0.42±0.27 0.50±0 0.62±0.22 0.50±0 
Decision Tree  0.23±0.22 0.62±0.11 0.36±0.26 0.69±0.12 0.52±0.14 0.74±0.11 
KNN  0.35±0.22 0.67±0.08 0.26±0.27 0.68±0.09 0.64±0.20 0.83±0.10 
Adaboost  0.27±0.28 0.66±0.12 0.32±0.23 0.73±0.10 0.62±0.13 0.73±0.14 
Random 
Forests 
 MCC AUC 
 0.30±0.30 0.79±0.10 
 
selection, the SVM models outperformed the other classifiers in terms of MCC. Under 
these two feature selection methods, the decision tree and Adaboost models showed 
better performance for RNAseq data than for RPPA data, but KNN was not notably 
different. In the majority of cases, scaled data showed better performance, and the second 
scaling method was more often better than the first.   
4.4.2. Commonly Selected Features and Functional Analysis 
The existence of well-performing models implies that the selected features are of 
functional importance. The five RPPA SFS models were compared, and 11 features were 
selected in at least two models. All of these have been associated with HNSCC in the 
literature: AR [205], C-Raf [206], CDK1 [207], Cyclin B1 [208], MAPK_pT202_Y204 
[1], N-Cadherin [209], PDK1 [210], PI3K-p85 [211], VEGFR2 [212], c-Jun_pS73 [213], 
and p27_pT198 [214]. In particular, AR was selected by four models, CDK1 and Cyclin 
B1 by three, and the others by two. Table 4.4 shows the number of total common features 
between each model pair. The low counts show that some models achieved comparable 
performance using very different feature sets. Even greater feature diversity was observed 
for the RNAseq SFS models. Among the four models, 52 features were present in total, 
but only two features were selected in more than one model: FAM27B and KRTAP17-1.  
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Table 4.4: Comparison and functional analysis of the RPPA SFS models:  
The number of features, GO functional annotations, and pathways (KEGG and 
Reactome) in common between different models are indicated. 













































GO terms: 15 
KEGG: 25 
Reactome: 208 
- - - 
Features: 2 









GO terms: 1 
KEGG: 12 
Reactome: 126 
- - - - 
Features: 2 





GO terms: 0 
KEGG: 0 
Reactome: 131 
- - - - - 
 
Functional analysis of the SFS feature sets was performed via DAVID and 
Reactome. DAVID was used to find significantly enriched Gene Ontology (GO) terms 
and KEGG pathways, while Reactome also returned significant pathways. In terms of 
specific features and GO terms, the five RPPA SFS models were diverse, with relatively 
few commonalities. However, many common pathways were found, both through KEGG 
and through Reactome. Seven KEGG pathways were common among the SVM, decision 
tree, and KNN RPPA models. These consisted of three signaling pathways: ErbB, 
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neurotrophin, and insulin signaling, and four cancer-related pathways: pathways in 
cancer, colorectal cancer, pancreatic cancer, and chronic myeloid leukemia. Reactome 
returned many more significant pathways than DAVID, and 46 pathways were in 
common among all five models. Most of these related to signal transduction and mitotic 
progression.  
Notably, there were no results in DAVID for the four RNAseq feature lists from 
the SFS models. Reactome returned results for only the KNN RNAseq model. The nine 
pathways identified fell into four categories: regulation of gene expression and 
development in beta cells, visual transduction and phototransduction, retinoid metabolism 
and transport, and the synthesis of bile acids and bile salts. Retinoids are important 
therapeutics for many cancer types, including HNSCC [215], and recent studies have 
shown that bile acids may be associated with head and neck cancer [216, 217].  
4.4.3. Integrated Analysis 
The results for developing SFS models based on naïve combination of the RPPA 
and RNAseq datasets are shown in Table 4.5. All of the models outperformed the 
corresponding RPPA SFS models for the same classification method in terms of mean 
MCC values. However, only the SVM models showed improvement over the RNAseq 
SFS models as well. Moreover, only the models for the smaller composite dataset (221 
features) utilized both RPPA and RNAseq features. The RPPA features selected by the 
SVM model for the smaller composite dataset were Cyclin B1 and p38_pT180_Y182. 
Cyclin B1 was one of the commonly selected features among the RPPA SFS models; p38 
is a mitogen-activated protein kinase that has also been associated with HNSCC [218]. 
The models for the larger composite dataset (767 features) selected only 
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Table 4.5: Performance evaluation of alternative predictive models using two composite 
RPPA and RNAseq datasets. Legend: scaled (1), scaled (2). 
Classification 
Method 
 SFS (221 features) SFS (767 features) 
  MCC AUC MCC AUC 
SVM  0.68±0.15 0.82±0.09 0.70±0.21 0.82±0.14 
Decision Tree  0.50±0.20 0.75±0.13 0.46±0.16 0.69±0.10 
KNN  0.53±0.21 0.77±0.11 0.64±0.26 0.83±0.13 
 
RNAseq features. Thus, the improvement in MCC seen for the best-performing model 
(SVM with the larger composite dataset) cannot be attributed to integrating data types, 
but may be due in part to using scaled data.  
Figure 4.2 compares the performance of single-data type models (RPPA and 
RNAseq) with ensembles comprised of only RPPA models, only RNAseq models, or 
both. The last category contains all possible ensembles with three to nine member 
models. Results represent the mean performance of 10-fold CV for the 209 common 
patients in the RPPA and RNAseq datasets, across 100 repetitions. The best single-data 
type ensembles had higher mean MCC values than individual models of that data type. 
Additionally, combination ensembles of multiple sizes were found which had better 
performance than any of the single-data type ensembles.  
The performances of the RPPA-only ensembles were compared in terms of the 
previous functional analysis results. For example, the best performing RPPA-only 
ensemble (SVM, KNN, Adaboost) achieved a mean MCC value of 0.54, and 50 
Reactome pathways were in common among the three feature sets. The worst-performing 
ensemble (SVM, Naïve Bayes, decision tree) had a mean MCC of 0.25 and 86 Reactome 
pathways in common. Among the RPPA-only ensembles overall, a correlation of -0.44 




Figure 4.2: Comparison of individual and ensemble model performances over 100 
repetitions of 10-fold CV. Combination ensembles, which allow for heterogeneity in both 
data type and component model type, outperform RPPA-only and RNAseq-only models. 
 
common among the ensemble member models. 
While the RNAseq ensembles had the highest median performance, several 
combined RPPA and RNAseq ensembles had higher overall performance. Among all of 
the ensembles tested – RPPA only, RNAseq only, and combination – 27 ensembles were 
identified which had better performance than the best-performing individual RNAseq 
model in more than 90 of the 100 CV repetitions. Of these, two were RNAseq-only 
ensembles. Another two were combination ensembles containing three and four models, 
respectively, in which only RNAseq models were chosen as members. The other 23 
notable ensembles all contained both RPPA and RNAseq member models.  
Among these 23 was the best performing ensemble overall, which achieved a 
mean MCC value of 0.80. This is higher than any of the model performances reported for 




























a. individual rppa models
b. individual rnaseq models
c. rppa-only ensembles
d. rnaseq-only ensembles
e. combination ensembles (3 models)
f. combination ensembles (4 models)
g. combination ensembles (5 models)
h. combination ensembles (6 models)
i. combination ensembles (7 models)
j. combination ensembles (8 models)
k. combination ensembles (9 models)
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ensemble model with those of the highest performing RNAseq (KNN) and composite 
(SVM) models [219]. In both cases, the improvement was statistically significant (p < 
0.01). This particular ensemble incorporated the Adaboost RPPA SFS model and the 
SVM, KNN, and Adaboost RNAseq SFS models. 
4.5. Discussion and Key Innovations 
In this study, I have performed an in-depth analysis of HNSCC RPPA data by 
implementing six different classification methods, using nested cross-validation to 
optimize parameters, and testing three alternative feature selection methods. This 
supervised approach contrasts with previous HNSCC studies using RPPA data, which 
have conducted unsupervised and differential expression analyses [180, 181]. It also 
differs from previous supervised studies on RPPA data [182, 183] in two ways. First, this 
study assesses the performances of several different combinations of feature selection 
methods and classification algorithms in order to identify the potentially relevant protein 
feature sets. Second, this study builds upon current research by developing integrated 
proteomic and transcriptomic models, and comparing them to RPPA-only and RNAseq-
only models. In particular, I performed two types of integrated analysis: one by direct 
combination of RPPA and RNAseq data, and another by constructing ensemble models 
using both data types. To my knowledge, this is the first such comparative, integrated 
study for modeling progression in HNSCC.  
From a modeling perspective, this study identified the integrated ensemble 
approach with both RPPA and RNAseq models as the best overall. The top-performing 
model for predicting HNSCC pathological stage was obtained using this approach, and 
had a statistically significant higher MCC value than the best performing individual 
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RNAseq and composite models. Notably, modeling results appear to support the initial 
conjecture that less functional agreement among the feature sets of member models will 
be associated with better performance. First, the RNAseq-only and the combination 
RPPA and RNAseq ensembles were observed to outperform the RPPA-only ensembles. 
Second, a moderate negative correlation was observed between the performances of 
RPPA-only ensembles and the numbers of common Reactome pathways among ensemble 
members. These observations indicate that higher-performing ensembles tended to be 
more functionally diverse in terms of member model feature sets. Investigation on larger 
datasets, as well as assessment using ensemble diversity measures and different ensemble 
construction techniques [220], are directions for further research. More rigorous 
examination of how and why different classifier and feature selection method 
combinations tend to vary in performance on RPPA and RNAseq data is also an 
important task.  
A related question of interest is performing multi-class classification to study bio-
molecular expression patterns among individual HNSCC stages, rather than grouping 
them into early and advanced disease. Another is investigating the differences between 
normal and early stage HNSCC samples. For investigating these questions, the 
availability of sufficiently large – in terms of both patients and features – public datasets 
is a constraint. While matched tumor and normal RNAseq data is available on TCGA for 
HNSCC, RPPA data for matched normal samples is yet unavailable. In addition, an 
inherent limitation of RPPA data is that only a selected set of proteins is measured. A 
larger set of proteins could enable discovery, in that proteins which were previously not 
implicated in HNSCC – or cancer in general – might be identified as informative features 
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through modeling. TCPA is currently in the process of extending their antibody set to 
cover 500 proteins [126], which will help to address this limitation to some extent. The 
availability of more extensive proteomic data for HNSCC through mass spectrometry is a 
related promising avenue. The Clinical Proteomic Tumor Analysis Consortium 
(CPTAC), like TCPA, is currently building a proteomic complement to TCGA. CPTAC 
hosts a library of LC-MS/MS data from tumor samples that are also in TCGA. At the 
time of writing, data from breast cancer, ovarian cancer, colon adenocarcinoma, and 
rectum adenocarcinoma have been released. Future availability of such data for HNSCC 
would be valuable to researchers.  
From a systems biology perspective, investigating multiple types of –omic 
datasets to gain insight into disease processes is an important area of research. Numerous 
individual proteins and genes selected as features in well-performing models in this study 
have been previously associated with HNSCC in the literature, including in a recent 
large-scale study by The Cancer Genome Atlas Network [221]. Additionally, functional 
analysis of the features selected in the top-performing models revealed notable patterns. 
Many processes – e.g., signal transduction pathways including those through EGFR and 
ERBB2, and events related to mitotic progression – were commonly represented among 
the RPPA model features. The RNAseq feature sets were much more diverse, but some of 
the associated biological processes have still been linked with HNSCC in the literature.  
While this integrative modeling study of RPPA and RNAseq data can provide 
guidance for further research, integration in general should be interpreted with caution. 
Because RPPA is a tool for functional proteomics, it is several biological steps removed 
from the mRNA counts measured by RNAseq, and mRNA is itself distinct from genome-
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level factors. Thus, further investigation into additional data types – e.g., copy number 
variations, mutations, DNA methylation, protein subunits and alternative activation 
states, metabolites – is needed for drawing conclusions about the specific mechanisms 
underlying HNSCC progression. Appropriate comparison and combination of multiple 
data types will help to fill in the gaps and provide greater insight into the process of 
disease development. By harnessing the diverse data from initiatives like TCPA, TCGA, 
and CPTAC, bioinformatics studies can lead to better understanding of the molecular 
bases of HNSCC and also other cancers.  
The Key Innovations of this chapter are: 
 Performed the first supervised modeling study for modeling progression in 
HNSCC by integrating both proteomic and transcriptomic data 
 Developed between-omic level integrated ensemble models with significant 













SUPERVISED LEARNING MODELS FOR EARLY DETECTION 
USING TRANSCRIPTOMIC DATA MODELS  
5.1. Transcriptomic Modeling Research in HNSCC 
Investigation of gene expression patterns in HNSCC is an active area of research, 
with numerous studies conducted using gene expression microarrays within the last 10 
years [222].  More recently, transcriptomic research has shifted towards RNA sequencing 
(RNAseq) because of its high sensitivity and dynamic range [223]. However, due to 
variations in the sample population, small samples sizes, and differences in experimental 
design and analysis methods, different transcriptomic studies on the same disease may 
report notably different lists of significant or key genes [224]. For this reason, integrated 
analysis of multiple transcriptomic studies is necessary for identifying consistent, 
fundamental gene expression patterns that indicate HNSCC status.  
Previous predictive modeling studies have applied gene expression data to various 
problems related to HNSCC, including predicting metastatic disease [225, 226], the 
development of cancer in patients with oral premalignant lesions [38, 39], and the risk of 
recurrence and relapse [227, 228]. A key aspect of HNSCC research is early detection: if 
the cancer is detected at an early stage, patient response to treatment is relatively high, 
and five year survival rates for multiple disease subsites exceed 80% [14, 37]. However, 
most cases are detected only at locally advanced stages, which are associated with much 
worse outcomes. For the same disease subsites, survival for locally advanced cases 




Figure 5.1: Modeling workflow describing roles for microarray, RNAseq (all stages) and 
early-stage RNAseq datasets 
 
conventional visual and tactile examinations [229]. Effective supervised models for 
predicting HNSCC status – and in particular, for differentiating early-stage HNSCC 
patients from healthy individuals – based on molecular data could be useful clinical tools.  
In this chapter, I present an integrated transcriptomic analysis of HNSCC, with 
the goal of developing robust predictive models for determining disease status. Because 
the lack of early stage samples is an obstacle, models are initially developed for 
predicting HNSCC status in general, and are then applied to predict early stage HNSCC 
in particular. The workflow for this study is shown in Figure 5.1. First, differential 
expression (DE) analysis was performed on several microarray datasets to identify 
common DE genes and to investigate the extent of variation among datasets. Second, 
classification models optimized on one microarray dataset were implemented on the 
others, in order to evaluate within-platform model robustness. Third, individual and 
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ensemble classification models developed using the microarray datasets were applied to 
RNAseq data, to test (i) between-platform robustness, i.e., if informative gene feature sets 
and model structures are transferrable across data types and (ii) performance in detecting 
early stage HNSCC. Finally, well-performing models were integrated into a software tool 
with a graphical user interface in order to make predictive models more accessible to 
HNSCC researchers and clinicians.  
5.2. Microarray and RNAseq Datasets 
Gene expression microarray datasets were obtained from the Gene Expression 
Omnibus (GEO) and ArrayExpress public repositories. To increase consistency in the 
downstream analysis, datasets selected for study met the following criteria: (i) data was 
from patient samples, not cell lines; (ii) data from both diseased and normal samples were 
available; (iii) the raw, unprocessed data was available; (iv) an associated publication was 
available; and (v) Affymetrix array platforms were used. These filtering steps led to five 
candidate Affymetrix datasets. Of these, three were chosen for further analysis because 
they shared the Human Genome U133 Plus 2.0 (54,675 probes) or U133A (27,777 
probes) arrays, enabling direct comparison of probes. Only the 22,277 common probes 
were used for analysis. These datasets are described in Table 5.1. To obtain gene 
expression values, the raw .CEL files were processed with RMA in the Affymetrix 
Expression Console software.  
Table 5.1. Description of gene expression microarray datasets examined in study 
Dataset  Affymetrix Array Platform Samples Reference 
E-GEOD-9844  Human Genome U133 Plus 2.0  25 cancer, 12 normal [125] 
E-GEOD-6791  Human Genome U133 Plus 2.0  42 cancer, 11 normal 
 
[230] 
E-GEOD-23036 Human Genome U133A 2.0  63 cancer, 5 normal [231] 
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RNAseq data (Version 2) for HNSCC was obtained from The Cancer Genome 
Atlas (TCGA), along with associated clinical data. The data has been aligned using 
MapSplice and quantified using RSEM [189, 190]. Count data for 20,531 genes are 
available in this dataset. Un-normalized data was used for DE analysis, and normalized 
data for classification. At the time of analysis, matched tumor and normal RNAseq data 
was available for 40 patients. Of these, 17 patients were categorized as early stage 
(pathological stages I and II).   
5.3. Model Development 
 
Differential Expression Analysis and Feature Selection  
Both the two-sample t-test and Wilcoxon rank-sum test were used to identify DE 
genes between the HNSCC and normal samples in the microarray datasets. Multiple  
 
 
Figure 5.2: Schematic of nested cross-validation (nested CV) framework 
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testing correction was implemented by controlling the False Discovery Rate (FDR ≤ 
0.05) or by implementing Bonferroni correction (αBonferroni = 0.05). DE analysis was 
performed on the RNAseq data using edgeR (FDR ≤ 0.05) [192]. To evaluate consistency 
in gene expression patterns across datasets, the DE gene lists were compared to each 
other. For classification, features were selected via mRMR (minimum redundancy 
maximum relevance) from the microarray datasets, implemented using the FEAST 
toolbox in MATLAB [193-195]. The performance of each classification model was 
optimized for up to the top 50 features.  
 
Binary Classifiers 
Three binary classification methods were tested: k-nearest neighbors (KNN), 
support vector machine (SVM), and decision tree (DT). Optimal parameters for each 
model were selected via grid search from the ranges shown in Table 5.2, using a nested 
cross-validation scheme as shown in Figure 5.2. Optimization was performed with 
respect to the Matthews correlation coefficient (MCC), and the area under the ROC curve 
(AUC) is also reported for optimized models. All analyses were performed using 
MATLAB (Mathworks, Natick MA).  
 
Table 5.2. Classification model parameters examined via nested cross-validation 
Classification 
Method 
Parameters Set of values 
KNN Number of neighbors (K)   [                    ] 
SVM Kernel 
Soft margin cost (C) 
  for GBRF  
Kernels: linear, Gaussian radial basis function 
(GRBF) 
C   2m, m   [-2,-1,0,1,2] 
  2m, m   [-2,-1,0,1,2] 
Decision Tree (DT) Splitting criterion Criteria: Gini diversity index (GDI), Twoing rule, 




5.3.1. Evaluation of Model Robustness across Microarray Datasets 
The robustness of each model was first evaluated by testing the model on the 
other microarray datasets, i.e., those which were not used in its development. In order to 
avoid the issue of batch effects entirely, models were not applied to other datasets 
directly. Instead, the model parameters and feature set associated with the top performing 
model of each classifier type for dataset i were used to train a model on dataset j     
  , with      [      ], where n is the number of microarray datasets. In addition, this 
comparison was also carried out after combining the feature sets for alternative models. 
For example, such a model to be tested on E-GEOD-6791 would combine the optimized 
feature sets for both E-GEOD-9844 and E-GEOD-23036. The rationale behind this 
experiment is to test whether a composite feature library, defined as the union of optimal 
feature sets from multiple datasets, would help to improve average predictive 
performance on new incoming datasets.  
 
Application of Microarray-Developed Models to RNAseq Data 
Next, model robustness across data formats was investigated by applying 
microarray-developed models to RNAseq data from TCGA. As described for the 
microarray-only cross-performance tests, the model parameters and feature set associated 
with a given microarray model was used to train a model on the RNAseq data. In order to 
transfer the optimized microarray feature sets, microarray probes were mapped to 
RNAseq features on the level of gene symbols.  
In addition to testing the performance of the nine individual and nine possible 
feature combination-based models on RNAseq data, two ensemble modeling frameworks 
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– majority voting and stacking [220] – were tested. Majority voting is the simplest 
ensemble framework; given a set of predicted labels from alternative models, the 
ensemble-predicted label is the most-commonly predicted label. All possible 
combinations of the nine individual microarray models (three classifier types for three 
datasets) with at least three members were considered for voting-based ensembles, 
resulting in 511 alternative models. Stacking involves a two-step classification process. 
In the first step, label predictions are obtained from alternative models on the training 
data. This set of predicted labels serves as the features for a second classification model, 
which is used to generate the final predictions. Three stacking models were developed, 
using all nine individual microarray models as the first-level predictors, and SVM, KNN, 
and DT were tested as the three second-level classifiers. 
 
Tool Design 
The developed predictive models were integrated into a software tool with a 
graphical user interface (GUI) to make them more accessible to HNSCC researchers, and 
for easy application to new datasets. Users can apply previously developed individual or 
ensemble models to process incoming datasets, and then visualize and export the results.   
5.4. Model Performance 
Comparison of DE Gene Lists and mRMR Selections 
Notable differences were observed among the DE genes selected in each 
microarray dataset, as shown in Table 5.3. The more conservative Bonferroni method 
resulted in only 5 common DE genes among the three datasets: MMP1, ABCA8, MYO1B, 
ARHGEF10L, and SASH1; all of these have been associated with HNSCC in recent 
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Table 5.3. Comparison of DE Genes across Microarray Datasets 
 E-GEOD-6791 E-GEOD-9844 E-GEOD-23036  Common DE 
Genes 
 Bonferroni FDR Bonferroni FDR Bonferroni FDR  Bonferroni FDR 
T-test 213 5763 84 2451 273 3154  5 682 
Rank-
sum test 
14 6836 5 2759 0 3401  0 785 
 
literature [125, 231-234]. When applying FDR, more than 600 common DE genes were 
identified across the three datasets for both statistical tests. Functional analysis was 
performed on the common FDR gene lists using DAVID [202]. Although not statistically 
significant, the top 10 Gene Ontology (GO) terms selected for both sets included 
GO:0006915~apoptosis, GO:0008219~cell death, GO:0012501~programmed cell death, 
GO:0016265~death, GO:0043588~skin development. Overall, these results indicate that 
while there is substantial variation across the microarray datasets, the commonly-selected 
DE genes are relevant to HNSCC.  
This variation was also observed for the RNAseq data: 10,239 DE genes were 
identified in the RNAseq data through edgeR; 526 and 610 of these genes overlapped 
with the microarray common DE gene lists (FDR) for the t-test and rank-sum test, 
respectively. Some of the commonly selected DE features were also represented in the 
mRMR feature lists. The common DE genes selected using either test with FDR were 
compared with the top 50 mRMR-selected features for the three microarray datasets. The 
number of features in the intersection of these lists ranged from 17 to 23.  
5.4.1. Model Performance across Microarray Datasets 
Table 5.4 shows the performance of KNN models developed using one 
microarray dataset on the others. The top three rows show the performance of the KNN 
model optimized through nested CV for each dataset. For example, the best-performing 
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Table 5.4. Multi-Dataset Performance of KNN Models in terms of MCC (AUC) 







 E-GEOD-6791 E-GEOD-9844 
E-GEOD-
23036 






















 Average Cross-Dataset Performance 
 0.52 0.82 0.46 
● ●   - - 
0.90±0.18 
 (1±0) 









KNN model on the dataset E-GEOD-6791 was developed using the same dataset. This 
resulted in perfect performance on testing data, with MCC and AUC values of 1±0. The 
same model (i.e., KNN with a given parameter set and feature set) also performed well 
when applied to another dataset, E-GEOD-9844, giving MCC and AUC values of 
0.89±0.10 and 0.94±0.06. However, when applied to the third dataset, E-GEOD-23036, 
very poor performance was observed, with the mean MCC near zero and the mean AUC 
near 0.5. This example demonstrates the lack of model robustness across datasets. Similar 
patterns are observed for the other datasets for KNN, as well as for the DT and SVM 
models in Tables 5.5 and 5.6, respectively.  
The lower three rows of Table 5.4 show the model performances resulting from 
combining the optimal feature sets of the other two models. For example, the bottom-
most row shows that using the combined optimal feature sets of the E-GEOD-9844 and 
E-GEOD-23036 KNN models to develop a KNN model for E-GEOD-6791 resulted in 
MCC and AUC values of 0.84±0.17 and 0.95±0.05, respectively. While this is lower than 
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Table 5.5. Multi-Dataset Performance of DT Models through MCC (AUC) 







 E-GEOD-6791 E-GEOD-9844 
E-GEOD-
23036 

















 Average Cross-Dataset Performance 
 0.43 0.85 0.50 
● ●   - - 1±0 (1±0) 









Table 5.6. Multi-Dataset Performance of SVM Models through MCC (AUC) 







 E-GEOD-6791 E-GEOD-9844 
E-GEOD-
23036 



















 Average Cross-Dataset Performance 
 0.68 0.89 0.50 
● ●   - - 
0.90±0.18 
(1±0) 









the performance of the optimal model developed for E-GEOD-6791 itself, it is higher 
than the average cross-dataset performance observed from applying either of the two 
other models to this dataset. For this particular group of datasets, E-GEOD-6791 and E-
GEOD-23036 showed poor performance during cross-prediction tests with the other, 
while E-GEOD-9844 showed more stable performance. Similar trends for cross-
prediction are shown for all classifiers tested. Overall, utilizing a composite feature set 
108 
 
aggregated from multiple models appears to yield more robust predictions for previously 
unseen data. 
5.4.2. Performance of Microarray-Developed Models on RNAseq Data 
Overall, individual (non-ensemble) models developed using microarray data 
performed reasonably well on RNAseq data, as shown in Figure 5.3. This experiment 
tracks the distribution of mean MCC values of each model category across 100 
repetitions of 3-fold CV on the RNAseq dataset. The median performance of the KNN, 
DT, and SVM models when applied to the RNAseq data was 0.73, with the best results 
for any CV repetition approaching 0.86 (result set (a)). The feature combination approach 
(b) showed a slight increase in median performance, but also resulted in many low-
performing outliers. Voting using single-classifier models (c-e) showed slight increases 
in median performance – the KNN-only and DT-only ensembles achieved median 
performances of 0.78, and the SVM-only ensemble reached 0.81 – and also increases in 
 
Figure 5.3: Comparison of alternative individual and ensemble models developed from 
microarray data when applied to predict HNSCC vs. normal samples from RNAseq data.  
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Figure 5.4: Comparison of alternative individual and ensemble models developed from 
microarray data when applied to predict early stage HNSCC vs. normal samples from 
RNAseq data.  
 
the minimum performance. The combination voting approaches (f-l) had a trend of 
slightly increasing median performance and of lower variation as the number of models 
in the combination increased. The seven-, eight-, and nine-member ensembles had best 
overall median performances, ranging from 0.85-0.87. Among the stacking ensembles 
(m-o), the best median performance was observed with KNN as the secondary classifier.  
In total, 42 models were developed which had better performance than the best-
performing individual model (mean MCC = 0.8599) in at least 50 of the 100 CV 
repetitions. These models were part of the five-, six-, seven- and nine-member voting 
ensembles, which also had smaller amounts of variation than many of the other model 
categories. Most of these models had instances of statistically significant improvement 
         over the best-performing individual model, as assessed by Steiger’s Z-test 
[219].  
































f. combination voting (3 member)
g. combination voting (4 member)
h. combination voting (5 member)
i. combination voting (6 member)
j. combination voting (7 member)
k. combination voting (8 member)






Figure 5.4 shows the performance of the same models when applied to the early 
stage vs. normal RNAseq data, across 100 repetitions of 3-fold CV. Overall, 
performances are slightly lower and also more variable, reflecting the more challenging 
nature of the classification problem. Otherwise, similar trends were observed across the 
model categories. In terms of mean MCC, the median performance for the individual 
models (a) was 0.68. The median performances of the combination voting ensembles 
were in the range of 0.77-0.78.  Unlike in the previous experiment, no models had better 
performance than the best- performing individual model across any CV repetition (MCC 
= 0.89) for more than 50 of the 100 CV repetitions. This is due in part to the overall 
lower model performances in most categories, as well as the slightly higher value of the 
maximum individual performance for this experiment. However, almost all of the 
combination voting models and one stacking model (f-o) exceeded the median 




The suite of microarray models was integrated into a MATLAB GUI that allows 
users to (i) load a new dataset of interest, (ii) select a model developed using previously 
examined datasets, or compare all models, and (iii) implement the selected model(s) and 
visualize and export the results. Figure 5.5 shows a screenshot of the interface. The goal 
of developing this system is to enable HNSCC researchers, particularly those from more 
clinical-oriented, non-computational backgrounds, to take advantage of predictive 
modeling resources developed by the computational research community. In particular, 




Figure 5.5: Screenshot of tool interface, displaying import, analysis, visualization, and 
export capabilities. 
 
easier to implement ensemble approaches that improve overall performance.  
 
5.5. Discussion and Key Innovations 
Consistency among different studies lends support to research findings; in the 
same way, consistent performance among datasets increases confidence in a predictive 
model, and in the functional importance of the features that it utilizes. In this chapter, I 
developed predictive models for HNSCC using gene expression data that exhibit robust 
performance both within and between transcriptomic data types. Other recent 
transcriptomic HNSCC studies have also compared results across several datasets. De 
Cecco and colleagues used three microarray datasets to develop their model, and tested it 
on six other datasets, including TCGA RNAseq data [227]; however, the endpoint of 
interest in their study was risk of relapse, not diagnosis. Saintigny and colleagues tested 
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their model for risk of oral cancer development in leukoplakia patients on nine other 
microarray datasets [39]. In addition, neither of these studies considered multiple 
classification approaches and ensemble methods, as in this study. Ye and colleagues 
performed a meta-analysis across 63 HNSCC transcriptomic studies, considering 
premalignant lesions vs. normal samples, primary tumors vs. normal samples, and 
primary tumors vs. metastatic disease [125]; however, the study focused identifying key 
genes and pathways, and did not build predictive models. This study contributes to the 
existing literature on transcriptomic analysis for HNSCC by considering several 
alternative modeling frameworks for the endpoint of disease state, with an application of 
early diagnosis. Overall, multiple models with good performance (MCC ≥ 0.8, AUC ≥ 
0.8) were identified. In addition, I compared and identified ensemble strategies that 
increased model performance for differentiating both general and early HNSCC from 
normal samples.   
Another direction for further research is in the integration of protein and gene 
expression data for early HNSCC detection. Several recent studies have investigated the 
use of salivary RNA and/or proteins for detecting oral cancer [235-237]. Some of the 
salivary RNA markers validated in [235] – IL-1B, IL-8, and H3F3A – were also selected 
in the DE gene lists in this study, and IL-8 was one of the mRMR-selected features for E-
GEOD-9844. This observation is promising in both directions: applying other feature 
selection methods to the current group of datasets may reveal more previously-validated 
markers, and future validation studies may support the clinical relevance of features used 
in the current models. In addition, in Chapter 4, I have demonstrated that combining 
transcriptomic and proteomic models increases performance when predicting HNSCC 
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pathological stage [238]. Thus, models combining multiple –omic data types may also 
improve performance for early disease detection.   
While current results are encouraging, more systematic testing, comparison, and 
refinement of models will be possible with additional and larger datasets. The three 
microarray datasets investigated here collectively include only 158 samples, and the 
number of matched tumor-normal RNAseq samples currently available in TCGA is also 
limited. However, data availability – and particularly for early stage disease – is always a 
limitation in cancer research. Therefore, one of the design goals of the modeling tool is to 
continually update its collection of individual and ensemble models as users upload 
additional labeled transcriptomic data. In this sense, it can serve to accelerate 
translational research. In the process, the tool can also be expanded to accommodate data 
and models for other prediction endpoints, such as length of survival, recurrence, and 
response to alternative therapies. It can also consider specific subsets of HNSCC, such as 
HPV+ vs. HPV- disease [239]. Thus, it can become a central component of a future 
clinical decision support system for assisting in HNSCC diagnosis and treatment 
planning.  
The Key Innovations of this chapter are: 
 Performed within–omic level integrative modeling study using microarray and 
RNAseq data for detection of HNSCC  
 Translated ensemble models developed for discriminating between HNSCC and 
paired normal cases to the problem of early HNSCC detection 
 Implemented tool to facilitate model translation and use of ensemble 




DYNAMIC SYSTEM MODELS FOR PREDICTION OF RESPONSE 
TO COMBINATION ADJUVANTS 
6.1. Chemoprevention in HNSCC 
Currently, HNSCC treatment options include surgery, radiation, chemotherapy, or 
combinations of these treatments [8]. Many patients with locally advanced (stage III/IV) 
disease respond favorably to initial treatment, but later experience locoregional 
recurrence, secondary primary tumor (SPT) development, or metastatic disease [9-13]. 
Chemoprevention is defined as the application of natural or synthetic agents to delay or 
prevent cancer progression. Adjuvant chemoprevention therapies have been shown to 
improve overall and disease-free survival in HNSCC; however, toxicity is a limiting 
factor [49, 240]. Therefore, the identification of safe, non-toxic adjuvant therapies for 
chemoprevention in HNSCC is of great clinical interest.  
Because of these characteristics, natural compounds from dietary agents are 
promising as chemoprevention adjuvants for HNSCC. The primary catechin found in 
green tea, (-)epigallocatechin gallate (EGCG), has been shown to be an effective 
antioxidant and has a wide range of effects on signal transduction pathways implicated in 
cancer [240]. It affects multiple processes including cell proliferation and division, 
angiogenesis, and apoptosis. Recent phase II clinical trials have indicated that green tea 
extract is effective in preventing oral cancer development in patients with premalignant 
oral lesions [241, 242]. However, the effects of EGCG alone are limited by low oral 
bioavailability [54, 55, 243]. Thus, the identification of effective combinations of EGCG 
and other natural compounds is of interest, since natural compound combinations may 
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yield more-than-additive effects while maintaining low toxicity profiles. For example, 
green tea catechin in combination with curcumin, which is found in turmeric, has been 
shown to have synergistic apoptotic activity in larynx carcinoma cell lines [56]. EGCG in 
particular has been shown to synergistically increase apoptosis in HNSCC cell lines when 
combined with luteolin, an antioxidant found in many green vegetables [244], as well as 
with resveratrol, which is found in grape skins and red wine [53].    
6.1.1. Prediction with Dynamic System Models 
Predicting effective combinations of natural compounds is challenging due to 
their multi-target effects on complex biochemical signaling networks. Mathematical 
modeling for cancer is a diverse and growing area of research; although inherently much 
simpler than the complex biological systems represented, models provide tools for 
predicting outcomes and generating testable hypotheses [58-60]. Mathematical models 
can assist chemoprevention research by relating the activities of individual and 
combination agents to cellular-level responses, such as proliferation, survival, and 
apoptosis. For example, my prior work involved developing an agent-based model to 
predict the response of an HNSCC cell line to the combination of paclitaxel and the anti-
angiogenic compound 2-methoxyestradiol  (2ME2) [245]. These types of models may 
help to advance clinical research via the generation of specific, testable hypotheses, i.e., 
the response to alternative drug combinations, as well as the prediction of specific 
therapeutic targets that could increase favorable responses. In addition to the previously 
mentioned model, for HNSCC, models have been developed to predict the effects of 
radiotherapy [246, 247], and some models do so by incorporating clinical imaging data 
[248-250]. Other models focus on optimizing radiotherapy-chemotherapy combination 
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treatments [251, 252], and yet another focus is the prediction of nanoparticle drug uptake 
[253]. However, these models do not take into account the molecular pathway-level 
processes by which natural compounds exert their effects. In addition, previous 
mathematical models for chemoprevention for multiple cancer types mainly focused on 
cost-effectiveness, not biological effectiveness, and considered the effects of 
conventional chemotherapeutics [254-256].  
To address this issue, this study develops a multi-scale dynamic model for 
predicting the response to natural compound chemoprevention agents in HNSCC, based 
on their targeted effects on signal transduction pathways. In computational cancer 
research, multi-scale dynamic models are those which describe behaviors at multiple 
spatial scales, and potentially also across different time scales. Possible spatial scales 
encompass the atomic, molecular, cellular, tissue, organ, and patient levels.  The model 
developed here describes behaviors at the molecular and cellular levels. The model is 
applied to predict the combination effects of EGCG and resveratrol in several HNSCC 
cell lines. I also demonstrate how the multi-scale design enables use of the model for 
hypothesis generation, including the prediction of specific pathway targets and potential 
effective natural compound combinations. In addition, the initially developed multi-scale 
ordinary differential equation (ODE) model is then coupled to an agent-based model 
(ABM), which enables natural compound response prediction in complex, heterogeneous 
cellular environments. These models provide groundwork for advancing research into 





6.2. Model Development 
6.2.1. Cell Lines and Dose Response Data 
Dose response data from three HNSCC cell lines – Tu212, Tu686, and SQCCY1 
– were used to develop and test the model. For Tu212, the percentage of apoptotic cells 
(early and advanced apoptosis) was measured for six dosage levels for resveratrol and 10 
dosage levels for EGCG, as shown in Figure 6.1. The combination response was 
measured for four levels: 30µM EGCG with 10µM or 15µM resveratrol (abbreviated 
E30R10 and E30R15, respectively) and 40µM EGCG with 10µM or 15µM resveratrol 
(E40R10 and E40R15). For Tu686 and SQCCY1, the combination response was 
measured for 12 levels each: 15µM or 20 µM resveratrol with 30, 40, 50, 60, 70, or 
80µM EGCG. 
 
Figure 6.1: Dose response data for the Tu212, Tu686, and SQCCY1 cell lines. Image 




Available dose response data was separated into training and testing sets in order 
to estimate model parameters. Training data comprised of the EGCG-only and 
resveratrol-only dose response measurements, along with all but two of the combination 
responses. The remaining two responses were used for testing. For Tu212, ( 
 
)    
training-testing splits were evaluated, and for the other two cell lines, (  
 
)     splits 
were tested. Parameters were estimated by minimizing the root-mean-square error 
(RMSE) between the simulated and experimentally observed percentages of apoptosis. 
Two alternative optimization methods were tested, both with the constraint that all 
parameters be non-negative: sequential quadratic programming (SQP) and the genetic 
algorithm (GA). SQP is a deterministic, gradient-based optimization method in which a 
quadratic programming sub-problem is solved at each iteration. For SQP, a constant 
initial parameter estimate of         was used, where              [          ] . 
The GA is a direct-search optimization method which uses evolutionary mechanisms to 
explore the parameter space to approach a global minimum. The initial GA population 
had 1,250 entries, of which 250 were sampled from   [   ]; 250 were sampled from 
  [   ] , where   is twice the maximum value observed for the SQP-optimized 
parameters from any training-testing split for the Tu212 cell line; and 750 were obtained 
by adding normally distributed noise to the SQP-optimized parameters from all six trials 
for the Tu212 cell line:                         (  
       
  
)       [          ]. 
Pairwise Pearson correlations between optimal parameter estimates obtained through 
each trial and each optimization method were used to assess the consistency of estimates.  
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6.2.2. Single-Scale Models 
Two alternative models were considered to model the combination drug effects, 
using cellular-level processes only. In the first case, the living and apoptotic (both early 
and late apoptosis) cell dynamics are tracked by first-order ODEs, as shown in Table 6.1. 
EGCG and resveratrol effects are modeled through the apoptosis rate parameter       . 
The observed nonlinear effects are naively modeled through higher-order functions of 
natural compound concentrations.  
In the second case, the Combination Index (CI), a measure used to assess drug 
combinations, was applied, as shown in Table 6.2. The CI indicates whether the 
combined effect of two drugs is additive (CI = 1), synergistic (CI < 1), or antagonistic (CI 
> 1). Chou and Talalay related the CI to administered drug ratios [257, 258]. The training 
 
Table 6.1: Naïve ODE single-scale model 
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data was used to estimate the CI value and the Hill function parameters. The combination 
effect E for the testing data was then estimated using Nelder-Mead simplex direct search.  
6.2.3. Multi-Scale Ordinary Differential Equation Model 
The multi-scale ODE model modifies the naïve single-scale model by defining the 
division rate parameter          and the apoptosis rate parameter        as functions of 
molecular species known to regulate these processes. In addition, the targeted effects of 
EGCG and resveratrol are modeled. Thus, both cellular-level and molecular-level factors 
are considered. The molecular-level model describes a system comprised of signal 
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  are the amounts of drugs A and B in 
the combination, while        are the 
amounts of drugs A and B that would yield 
the same effect as the combination if each 
was administered alone. 
 
The Hill function of order hd relating the 
probability of response    to the drug 
concentration x is:       
   
         
  
. Using 
this to model the response curves of drugs A 
and B individually, the CI equation can be 





Figure 6.2: Signal transduction pathways represented in the molecular-level model 
 
transduction pathways known to be highly relevant in many cancers, including HNSCC. 
These are the MAPK/ERK pathway, PI3K-Akt signaling, and their effects on modulators 
of apoptosis including p53, Bcl-2, and BAD. Figure 6.2 shows this signaling network, as 
well as the points at which the effects of EGCG and resveratrol are modeled. Some 
molecular targets are affected by both agents. EGCG has been shown to induce p53 
expression in multiple cell types, and resveratrol is also associated with p53 activation 
[243]. In addition, both EGCG and resveratrol have been shown to inhibit NF-kB 
signaling [243], AP-1 activity [243, 259, 260], and PI3K-Akt [243, 261-263]. EGCG also 
inhibits phosphorylation of EGFR and association of Raf1 and MEK1 [243, 264]. 
Resveratrol has dose-dependent effects on phosphorylation of Erk1/2 [265, 266]. Table 
6.3 shows the generalized mass action model for this system, and the relationship 
between the molecular-level model and the cellular-level model.   
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   [ ][                  ]    [ ][                  ] 
This is of course a basic approximation of the complex biochemical interactions 
occurring in the signal transduction network. Here, X is assumed to be the activated (e.g., 
phosphorylated) form of the molecule. The differential equation is second-order because 
the process of de-activation (e.g., dephosphorylation) is being described implicitly. That 
is, the kinetic parameter    is assumed to represent the rate of activation 
by                    scaled by the proportion of X which has become de-activated, and 
which can thus be activated by association with                   . The same pattern is 
followed for the kinetic parameter    and                    . A more complete 
representation of the activation or inhibition processes could include separate variables 
and equations for the active and inactive forms of X. For example: 
[      ]  [ ]  [         ] 
 [ ]
  
   [         ][                  ]    [ ][                  ]    [ ] 
 [         ]
  
    [         ][                  ]    [ ][                  ]    [ ] 
In this representation, active X would be generated by the association of                    
with the inactive form of X, and it would be removed either by association with 
                   or natural degradation back to its inactive state, governed by the kinetic 
rate constant   . This representation also makes the simplifying assumption that the total 
amount of X (active and inactive forms) remains constant under the time-scale of interest. 
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Table 6.3: Multi-scale ODE model 
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12 molecular species. 
The multi-target effects 
of EGCG and 
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directly on the various 
biochemical entities in 
the pathway. The model 
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Again, the population is 
divided into living and 
apoptotic cells. Early 
and late apoptotic cells 
are pooled together. 
 
 
The division and 
apoptosis kinetic rate 
parameters are direct 





Another, even more complex and realistic representation could include protein 
transcription, translation, and degradation rates, as well as detailed enzymatic response 
patterns like Michaelis-Menten or multi-substrate kinetics. The reason for avoiding these 
representations is the lack of measured kinetic rate constants and the lack of time-series 
molecular expression data for estimating these parameters. This is problematic because 
the number of these parameters will increase as the model increases in complexity. In the 
future, as additional data become available, this foundational model can be expanded to 
accommodate more specific biochemical interactions of interest.  
6.2.4. Multi-Scale Agent-Based Model 
A key assumption behind ODE models is that the population is well-mixed, with 
no spatial gradients. This is appropriate for an in vitro study in which a homogeneous cell 
population is evenly distributed in its environment. However, research into natural 
compounds for chemoprevention also involves more complex in vitro environments (e.g. 
multicellular spheroids) and in vivo studies. ABMs are well-suited for representing 
heterogeneous cell populations, inter-cellular interactions, cell movement, and the 
complex spatial structure of tumors. The multi-scale ODE model was therefore used to 
develop a multi-scale agent-based model (ABM).  
In this ABM framework each agent represents a single cell. Instead of kinetic rate 
parameters, ABMs utilize transition probabilities, i.e., the probability that each agent 
experiences division (pd) or apoptosis (pa) during a given time step. The multi-scale ODE 
is used to drive the ABM by enabling estimation of the apoptosis probability at each time 
step. For the purpose of estimating pa, pd is assumed to be constant, based on the cell 
cycle duration of the Tu212 cell line (~24 hours). The fraction of apoptosis predicted by 
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Table 6.4: Coupling the multi-scale ODE and agent-based models 
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If    cells are initially 
present, total numbers 
of living and apoptotic 
cells after a certain 
number of time steps 
(T) are represented in 
terms of probabilities 




The overall probability 
of apoptosis (c) can be 
used to estimate pa. 
 
the ODE (for a homogeneous population of the agent-cell under consideration) defines c, 
the cumulative probability of apoptosis over the prediction timeframe. As shown in Table 
6.4, pa can then be estimated by minimizing the error e.  
In this manner, the ODE model for a homogeneous population can be used to 
govern the behavior of a single agent-cell, though it may exist in a heterogeneous 
population. In turn, population heterogeneity can also affect the behavior of single agent-
cells. While the multi-scale ODE provides the forward drive to the ABM, the ABM can 
also provide feedback to the ODE model. Characteristics of the tumor microenvironment, 
such as hypoxia, can significantly modulate the activities of signal transduction 
pathways, including EGFR and PI3K-Akt signaling, thereby affecting the behavior of 
individual cells [267, 268]. The hypoxic effect experienced by a single cell can be 
estimated through the spatial environment of the ABM, and fed back into the ODE, in 
order to more realistically model microenvironmental effects on individual cells.  
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6.3. Model Performance 
Multi-scale model outperforms single-scale models in predicting response to EGCG and 
resveratrol combinations 
As shown in Figure 6.3, the naïve single-scale model was unable to replicate 
experimentally-observed trends in either the training or testing sets, demonstrating poor 
performance overall. The CI-based model was able to make reasonable predictions of 







Figure 6.3: The performance of (a) the multi-scale model (RMSE = 0.0231), (b) the CI-
based single-scale model (RMSE = 0.0578), and (c) the naïve single-scale model (RMSE 
= 0.1529) for a trial on Tu212 data, in which the E30R10 and E30R15 samples were used 
in training the models, and the E40R10 and E40E15 samples were used for testing. 
RMSE values are based on the testing samples only. 
 

























































































perturbations. The multi-scale ODE model predictions of EGCG and resveratrol 
combination effects were more accurate than those of either single-scale model. This 
improvement in performance was observed across all six trials for the Tu212 cell line. 
Overall, the improvement in performance by the multi-scale model (GA-optimized) was 
statistically significant (      , Wilcoxon rank-sum test) compared to the CI-based 
and naïve single-scale models. The performance of the SQP-optimized multi-scale model 
was comparable; when discounting one outlier trial, it also showed statistically significant 
improvement over the single-scale models. Parameter estimates across trials and across 
optimization methods were generally consistent, exhibiting median Pearson correlation 
values exceeding 0.7.  
In addition, at the final simulation time step, the normalized ratios of pathway 
elements (with respect to EGFR) were compared to the normalized gene expression ratios 
for the combination treatment case. While the ratios alone cannot be used to ascertain the 
correctness of the model, the high Pearson correlation value (r = 0.89) between the 
simulated and experimental ratios implies that the model predictions remain in a 
reasonable region of the state space.  
 
SQP Optimization Shows Consistent Performance in Local Initialization Neighborhood  
The results shown in the previous section were based off of a constant initial 
parameter estimate of        , where             [          ]. Because the 
parameter optimization space may be complex and irregular, the effect of different 
initialization points on the SQP-based optimization was evaluated. The model 







Figure 6.4. (a) Comparison of the SQP optimization performance at different initial 
parameter estimates for the Tu212 cell line, and (b) correlation of the optimized 
parameters obtained from different initial estimates with those obtained from the initial 
estimate of            .  
 
for six alternative initialization points, as shown in Figure 6.4(a). Initializing at     
        ,           ,           , and             gave similar distributions of testing 





































correlation with parameters optimized using uniform initial parameter estimates of 0.1
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errors. Initializing at               and             gave an increased range of testing 
errors, and a much larger outlier value. Training errors (not shown) were consistently 
small for all initializations except for            .  
Additionally, initializations with              ,            , and             
yielded parameter estimates that had fairly high Pearson correlation values (median > 
0.8) with those estimated using            , as shown in Figure 6.5(b). Notably, during 
the other two cases of              and           , which were associated with higher 
testing error outliers and more variable correlations, stalling at low iteration counts was 
observed during the optimization process for some trials. 
 
Model-based Comparison of Cell Line Responses 
Alternative estimates of model parameters indicated differences in the responses 
of the three cell lines to the various combinations of resveratrol and EGCG. For example, 
Figure 6.5(a) shows the model predictions for the Tu686 cell line, using the parameters 
optimized for the Tu212 cell line. The combination response predictions track the 
experimental observations well, but the model over-predicted responses to treatment with 
resveratrol and EGCG individually, particularly for higher concentrations. This suggests 
that while Tu686 and Tu212 have similar responses to resveratrol and EGCG in 
combination, Tu686 is less sensitive to the individual treatments. Figure 6.5(b) shows the 
corresponding results for the SQCCY1 cell line; as for Tu686, the model over-predicted 
responses to treatment with resveratrol and EGCG individually. Moreover, compared to 
Tu686, the combination effect predictions for SQCCY1 when using the Tu212-optimized 
parameters were poorer. In comparison, model parameters optimized for the SQCCY1 
cell line effectively predicted combination responses, as shown in Figure 6.6, as well as 
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individual responses to resveratrol and EGCG (not shown). However, the SQCCY1- and 







Figure 6.5. Comparison of the experimental and predicted responses to resveratrol alone 
(left), EGCG alone (right) and the 12 combination treatments (bottom) using Tu212-
optimized parameters for (a) for the Tu686 cell line and (b) the SQCCY1 cell line.  
 




















































































































































Figure 6.6. Comparison of experimental and predicted responses to the 12 combination 
treatments for the SQCCY1 cell line. 
6.4. Case Studies 
One of the main goals of developing dynamic models of biological systems is to 
predict how the system may respond to alternative perturbations. A perturbation may 
represent, for example, the effect of a drug on specific reaction or on a group of reactions 
initiated by a common molecule. The model can then be used to rank alternative 
perturbations in terms of their predicted effect. In this sense, the model can identify 
potential drug targets and generate testable hypotheses. In the first case study, the multi-
scale ODE model is applied to predict which perturbations, in addition to the best-
performing EGCG-resveratrol combination (E40R15), can further increase the fraction of 
apoptotic cells for the Tu212 cell line.  
The experimental dose response data for EGCG and resveratrol in this study has 
been acquired from three HNSCC cell lines in vitro. In the second case study, the multi-
scale ABM is applied to predict how the apoptosis patterns for EGCG and resveratrol 
combinations may change in more complex cellular environments, by considering the 
microenvironmental factor of hypoxia. Hypoxia is associated with many negative effects, 
such as suppression of apoptosis and increased cancer cell survival, increased 

































angiogenesis and invasiveness, and decreased sensitivity to both radiotherapy and 
chemotherapy [267, 269]. In HNSCC in particular, hypoxia measures are associated with 
poorer overall and disease-free survival [269]. One of the key signal transduction 
pathways affected by hypoxia is PI3K-Akt signaling. In HNSCC, hypoxia has been 
shown to increase activated Akt expression both in vitro and in xenograft models; 
moreover, this effect occurs independently of upstream EGFR status [267, 270]. The 
second case study will mimic these effects by varying the initial relative Akt activity 
input to the internal ODE model driving each agent cell, as a function of the degree of 
hypoxia experienced by that agent cell.   
6.4.1. Target Prediction  
Using the Tu212 cell line response data, 14 parameters modulating inter- 
molecular interactions were selected for perturbation analysis. The parameters related to 
EGCG and resveratrol effects and the proliferation and apoptosis rates were held 
constant. Two types of perturbations were considered: doubling and halving the original 
parameter values. Each type of perturbation was applied to each of the ∑ (  
 
)      
       possible combinations of the 14 parameters. The combinations were ranked in 
terms of the fraction apoptosis observed after each perturbation.  For both the SQP- and 
GA-derived parameter sets, the same top two perturbations were identified, as shown in 
Figure 6.7. If only one process was perturbed, halving Akt-mediated inhibition of p53 
increased the predicted apoptotic fraction to above 0.75. If two processes were perturbed, 
halving Akt-mediated activation of NF-kB in addition increased the predicted apoptosis 
fraction to above 0.80. Further perturbations led to only slight increases in the predicted 







Figure 6.7: (a) The predicted apoptotic response from the top perturbation is shown in 
cyan, and the response for the top two perturbations is shown in magenta. (b) The 
processes within the signaling network targeted by each perturbation are highlighted in 
cyan and magenta, respectively. 
 
These predictions emphasize the importance of Akt-mediated signaling in 
HNSCC. For example, the Head and Neck Cancer Tissue Array Initiative has shown that 
Akt-mTOR signaling is often activated in HNSCC, independently of mutant p53 or 
EGFR [271]. Moreover, the Akt signaling pathway is a key mechanism by which the cell 



































can bypass inhibition of EGFR [272, 273]. That Akt-mediated processes were the top two 
ranked perturbation targets suggests that additional synergistic effects may be observed 
by combining EGCG and resveratrol with other natural compounds that target Akt 
signaling, such as curcumin, pomegranate, and lycopene [243]. For example, a recent 
study demonstrated that combining resveratrol with curcumin induced greater pro-
apoptotic effects in several HNSCC cell lines than curcumin alone [274].  
6.4.2. Spatial Feedback and Effects of Hypoxia 
The ABM was used to investigate how spatial structures and hypoxic effects 
might affect responses to the resveratrol and EGCG combinations. Figure 6.8 describes 
this workflow and the interaction between the ODE and the ABM.  
The first case involved a uniform random distribution of cells (Figure 6.9(a)),  
 
Figure 6.8: Feedback between the ODE and the ABM, based on estimation of the O2 

















Figure 6.9: (a) uniform randomly distributed cell population; (b) spherical cell 
distribution. Baseline fraction apoptosis patterns with no O2-based effects for (c) the 
uniform population and (d) the spherical population. Apoptosis fraction patterns with O2-























































































































similar to the in vitro cell culture environment, while the second case involved a spherical 
distribution of cells (Figure 6.9(b)), similar to a multicellular spheroid or avascular 
tumor. In the first case, an O2 gradient was imposed by simulating the presence of a blood 
vessel along the vertical axis, from which O2 diffused into the environment. In the second 
case, the O2 gradient results from diffusion into the sphere from the ambient environment. 
In both cases, the O2 gradients were calculated following the models and parameters in 
[275, 276]. The effect of hypoxia on Akt activity was modeled as a linear function of the 
O2 gradient.  
In the case with randomly distributed cells, the fraction apoptosis predicted by the 
ABM when no hypoxic effects where present matched the experimental observations for 
the Tu212 cell line, as shown in Figure 6.9(c). In the case with cells arranged in a sphere, 
the baseline fraction apoptosis, with no O2 gradient, was predicted to be higher, as shown 
in Figure 6.9(d). This is reasonable because cell proliferation is restricted in the interior 
of the sphere due to cell crowding, while apoptosis is not. In both scenarios, the model 
predicted that even moderate increases in Akt activity (10-50%) could result in notable 
decreases in the predicted fraction of apoptotic cells. Figure 6.9(e-f) show the predicted 
response patterns when the O2 gradient resulted in a maximum 20% increase in Akt 
activity for hypoxic cells. These predictions are supported by recent findings that the pro-
apoptotic activity of curcumin, which affects many of the same pathways as EGCG and 






6.5. Gene Expression Analysis 
RNAseq analysis was used to implicate additional genes and processes for future 
expansion and refinement of the model. RNAseq data was available for four samples: no 
treatment, resveratrol-only, EGCG-only, and one combination (E40R15). Bioconductor 
packages were used to annotate sorted BAM files using the hg19 reference sequence 
from UCSC and to count reads. Differential expression analysis was performed using 
edgeR [192] to compare each treatment case against the no treatment case, with an FDR 
threshold of 0.05. Functional analysis of differentially expressed gene (DEG) lists was 
performed using DAVID [202].  
The synergistic effect of EGCG and resveratrol is apparent through the pattern of 
DEGs observed for individual and combination treatments, as shown in Table 6.5. EGCG 
treatment alone led to 54 DEGs, and resveratrol alone led to 111 DEGs. The combination 
treatment led to a more than four-fold increase, with 466 DEGs. Among all three lists, 22 
genes were in common. The DEGs associated with combination treatment also 
represented a larger variety of biological processes, as shown by Gene Ontology (GO) 
mining in Table 6.6. 19 GO terms were implicated with the combination treatment DEG 
list. Among these, two terms were also implicated in the EGCG DEG list, and four in the 
resveratrol DEG list. Key processes implicated include regulation of cell proliferation,  
 
Table 6.5: Common DEGs for three treatment cases vs. no treatment (NT) 
 
  NT vs. EGCG NT vs. Resveratrol NT vs. 
Combination 
NT vs. EGCG 54 23 48 
NT vs. Resveratrol - 111 81 




Table 6.6: Significant Gene Ontology terms associated with the DEG list for the no 
treatment vs. combination case. Terms also associated with the EGCG and resveratrol 
DEG lists are marked. 
GO:0006955~immune response  
GO:0009611~response to wounding  
GO:0006952~defense response 
GO:0010033~response to organic substance   
GO:0006954~inflammatory response 
GO:0042127~regulation of cell proliferation     
GO:0048545~response to steroid hormone 
stimulus 
GO:0031960~response to corticosteroid 
stimulus  
GO:0042981~regulation of apoptosis    
GO:0009719~response to endogenous 
stimulus 
GO:0043067~regulation of programmed 
cell death  
GO:0070482~response to oxygen levels  
GO:0010941~regulation of cell death   
GO:0009615~response to virus     
GO:0051384~response to glucocorticoid 
stimulus  
GO:0001893~maternal placenta 
development   
GO:0001666~response to hypoxia   
GO:0030595~leukocyte chemotaxis 
GO:0050900~leukocyte migration   
 
apoptosis, and cell death. Notably, the response to oxygen levels and hypoxia are also 
included in this list. Overall, the results of RNAseq analysis clearly indicate that the 
combined effect of EGCG and resveratrol is much more extreme and wide-reaching than 
the effects of either alone.  
6.6. Discussion and Key Innovations 
This chapter proposes a multi-scale ODE model for predicting and studying the 
combination effects of natural compounds for HNSCC chemoprevention. The model 
successfully predicted the combination effects of EGCG and resveratrol in three HNSCC 
cell lines. In addition, a multi-scale agent-based model was developed in order to couple 
the predictions of the ODE with feedback from spatially heterogeneous and complex 
cellular environments. Case studies applied these models to predict the effects of 
additional targeted interventions and the effects of microenvironmental hypoxia on cell 
population response.  
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Multi-scale models of cancer, which can encompass scales from the atomic to the 
patient level, are valuable tools for quantitatively predicting outcomes and generating 
testable hypotheses. Many recent models have focused on specific processes in cancer 
biology, such as invasion [278, 279], angiogenesis [280], and metastasis [281]. Others 
have focused on specific cancer types. For example, models of brain cancer and non-
small cell lung cancer have related the interaction dynamics of EGFR, TGF-α, PLC-γ, 
and other molecules to proliferative or migratory cell phenotypes [282-284]. Models 
which consider drug response range from focusing on conventional chemotherapeutics 
[285, 286] and radiotherapy [287] to those describing the effects of targeted therapeutics, 
such as a tyrosine kinase inhibitor against EGFR [282], the anti-angiogenic agent 
endostatin [280], anti-invasive matrix metalloprotease [279], and antiandrogen therapy 
[288]. I distinguish the current study from prior art in two ways. First, from a biological 
and clinical perspective, this model focuses specifically on HNSCC and in particular on 
chemoprevention, not on conventional therapeutics. Second, from a modeling 
perspective, this model focuses on the complex effects of natural compounds, which 
interact with the biochemical system at multiple points, rather than targeted therapeutics.  
The current results highlight several key directions for future research. First, 
RNAseq analysis revealed that the combination effects of EGCG and resveratrol are 
much more extensive than the individual effects of either. Further research into these 
effect patterns – particularly at the protein and metabolite levels – will yield greater 
insight into the mechanisms of these natural compounds, and will indicate how they can 
be more effectively applied in clinical settings. As additional data – particularly the 
kinetic parameters governing molecular-level processes – become available, the current 
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models can be expanded and refined to include more biological details. For example, the 
molecular pathway modeled here omits some intermediate mechanistic steps, such as the 
role of IKK in the activation of NF-kB, and that of MDM2 in inhibiting p53. These and 
other interactions have relevance to how EGCG and resveratrol exert their effects [289-
292]. As such, they are important in interpreting model predictions, particularly target 
predictions. Another motivation for model expansion is that all three HNSCC cell lines 
modeled here are p53 mutants. As more information is gathered on the effects of mutant 
p53 losses and gains of function on other components of the signal transduction network, 
these cell line-specific effects can be incorporated into the model [293, 294]. Next, as the 
model predictions indicate, the response to EGCG and resveratrol may be dampened in 
more complex in vitro and in vivo settings, due to microenvironmental and other factors. 
This is a multi-faceted challenge, and potential solutions include combination with other 
natural compounds or targeted agents, as suggested by the first case study, as well as the 
development of effective drug delivery and cell-targeting strategies.  
In the long term, as these challenges are addressed, models for predicting natural 
compound chemoprevention response could become part of a personalized treatment 
planning system for HNSCC patients. Such models could take into account patient-
specific clinical data and –omic expression signatures in order to predict regimens of 
effective, non-toxic chemoprevention adjuvants. The current modeling study provides the 
groundwork for the development of such a system, with the overall goal of preventing 
recurrence, SPT development, and metastasis, and improving HNSCC patient outcomes.  
The Key Innovations of this chapter are: 
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 Developed first multi-scale models for predicting the combination effects of 
natural compounds in HNSCC 
 Tested multi-scale ODE model on dose response data from three HNSCC cell 
lines, and extended it to generate a  multi-scale ABM 
 Demonstrated application of ODE and ABM models for target prediction and 























The concrete goals of this dissertation were to develop mathematical modeling 
tools for mining –omic datasets and for the analysis of biological system behavior in the 
context of HNSCC. The specific technical achievements of this dissertation 
corresponding to the three research objectives are:  
1. Development and validation of mathematical modeling tools for knowledge-
driven exploratory data mining of transcriptomic, proteomic, and metabolomic 
datasets, in terms of both explicit (hypergeometric similarity measures, 
DetectTLC) and implicit (DetectTLC) similarity-based analysis 
2. Construction of predictive models using integrated analyses between –omic levels 
to discriminate between early and advanced HNSCC, and within –omic levels for 
developing robust predictive models applicable to early disease detection 
3. Development and validation of integrated molecular- and cellular-level ordinary 
differential equation model for predicting the response to natural compound 
adjuvants in HNSCC cell populations, and extension to an agent-based model for 
prediction under different microenvironmental conditions 
7.1. Concrete Innovation Deliverables 
 
The key innovations of this dissertation, as noted at the closing of each chapter, 
are summarized below:  
 (Chapter 2) Development of binary hypergeometric similarity measure using 
Fisher’s exact test 
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 (Chapter 2) Development of multivariate hypergeometric similarity measure using 
the Fisher-Freeman-Halton test 
 (Chapter 2) Development of a piecewise approximation algorithm to facilitate 
application of the multivariate hypergeometric similarity measure to high-
dimensional data vectors 
 (Chapter 2) Implementation on two HNSCC (transcriptomic and proteomic) and 
one non-HNSCC (MSI, lipidomic) datasets indicates that proposed multivariate 
hypergeometric similarity measure makes relevant selections not identified by 
other similarity measures 
 (Chapter 3) Development of the first analytical pipelines using quantitative image 
features for identifying m/z images containing spot-like regions in MSI data 
 (Chapter 3) Design, implementation, and validation of the first software tool, 
DetectTLC, for enabling and accelerating TLC-MSI studies in metabolomics by 
automatically finding mixture components of potential interest in TLC-MSI 
datasets 
 (Chapter 4) Performed the first supervised modeling study for modeling 
progression in HNSCC by integrating both proteomic and transcriptomic data 
 (Chapter 4) Developed between-omic level integrated ensemble models with 
significant improvement in performance for predicting HNSCC pathological stage 
 (Chapter 5) Performed within–omic level integrative modeling study using 
microarray and RNAseq data for detection of HNSCC  
 (Chapter 5) Translated ensemble models developed for discriminating between 
HNSCC and paired normal cases to the problem of early HNSCC detection 
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 (Chapter 5) Implemented tool to facilitate model translation and use of ensemble 
transcriptomic models in the HNSCC research community 
 (Chapter 6) Developed first multi-scale models for predicting the combination 
effects of natural compounds in HNSCC 
 (Chapter 6) Tested multi-scale ODE model on dose response data from three 
HNSCC cell lines, and extended it to generate a  multi-scale ABM 
 (Chapter 6) Demonstrated application of ODE and ABM models for target 
prediction and prediction of response in complex environments, respectively 
 
Figure 7.1 demonstrates how these deliverables map to both clinical 
challenges and technical challenges in HNSCC research.  
 
 













7.2. Concrete Publication Deliverables 
 
The section provides a comprehensive list of publications completed during my 
years as a Ph.D. student. Those which contribute directly to this dissertation are 
highlighted in Table 7.1.  
 
Table 7.1: Overview of publications related to dissertation 
Specific 
Aim 
Sub-Aim Citation Publication Type Publication Status 
1 
Binary hypergeometric similarity measure [C1] Conference paper Published 
Multivariate hypergeometric similarity 
measure 
[J2] Journal paper Published  
DetectTLC [J6] Journal paper In preparation 
2 
Early stage vs. normal: microarray and 
RNAseq data 
[C6] Conference paper 
Accepted for 
Publication 
Early vs. advanced stage: gene and protein 








Single-scale, cellular-level cancer model [C3] Conference paper Published 
Multi-scale chemoprevention model [J7] Journal paper In preparation 
  
Published or Accepted for Publication 
 
Journal Papers 
[J1] Quo CF, Kaddi C, Phan JH, Zollanvari A, Xu M, Wang MD and Alterovitz G 
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7.3. Directions for Future Research and Concluding Remarks 
 
The models and tools developed in this dissertation are complete and fully 
functional. However, the critical final step in a research project is to recognize potential 
future applications and extensions of the current work. Some specific avenues for further 
inquiry were mentioned in the discussion sections concluding each chapter. Here, I 
elaborate on opportunities in two dimensions: (1) basic and translational research in 
HNSCC and (2) the design and development of novel mathematical models.  
7.3.1. Basic and Translational Research in HNSCC 
One of the major goals of Big Data research in biomedicine is biomarker 
identification, for specific and practical applications like early diagnosis, patient 
stratification, and prediction of treatment response. Applying the modeling infrastructure 
developed in this dissertation to new, more comprehensive –omic datasets can greatly 
facilitate these tasks: 
 
Early Disease Detection with Transcriptomic, Proteomic, and Metabolomic Data 
Because of the differences in HNSCC outcomes according to the stage at which 
the disease is detected, molecular marker-based systems for early diagnosis of HNSCC 
could have a large clinical impact. This is particularly important for disease subsites for 
which early disease symptoms may be limited, like the oropharynx, or for which 
symptoms may be misattributed, as in the oral cavity [295, 296]. Overlap between the 
transcriptomic features identified in Chapter 5 and validated salivary mRNA markers for 
detecting oral cancer [235] is encouraging, and establishes the stage for clinical 
validation of other transcriptomic features highlighted through the models developed in 
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this research. In addition, Chapter 4 demonstrated that the integration of proteomic and 
transcriptomic data can assist in stage prediction. This between-omic level integration 
may also assist in the problem of early diagnosis, once proteomic data for matched early 
and normal patient samples becomes available. Incorporating metabolomic data into 
these models is also worthy of investigation.    
 
Integration of Mass Spectrometry Imaging and Natural Compound Chemoprevention 
Research 
The potential of MSI in HNSCC research is immense, and informative model-
driven experiments could immediately follow the acquisition of MSI datasets from 
HNSCC samples. Possible experimental settings include tumors, xenografts, or 
spheroidal cultures. MSI enables combined molecular and spatial analysis. This could be 
particularly informative following treatment with bio-active natural compounds. Chapter 
6 developed a multi-scale ABM, which is a spatial model that could be applied to 
understand and predict spatially heterogeneous molecular expression and cellular-level 
response patterns observed in MSI data. In addition, the similarity measures developed in 
Chapter 2 could be applied to assess spatial molecular expression patterns across tissue 
regions (i.e., tumor, marginal, and surrounding normal), as well as among regions 
showing different degrees of response to administered natural compounds.   
 
Integration of TLC-MSI and Chemoprevention Research 
Another key direction for research is the investigation of lipid and metabolite 
profiles in HNSCC. The natural compounds being investigated for HNSCC 
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chemoprevention affect multiple biochemical entities, both directly and indirectly. For 
example, recent studies have indicated the importance of lipid rafts to the effects of 
EGCG and resveratrol on downstream signaling [297, 298]. The DetectTLC system 
developed in Chapter 3 provides a computational framework for investigating the effects 
of natural compounds on lipids and metabolites, and hence for obtaining a better 
understanding of their mechanisms of action. 
 
Applications of Similarity Measure in Biomedical Image Analysis 
The multivariate hypergeometric similarity measure introduced in Chapter 2 may 
also be applied to other data types in addition to molecular expression –omic data. One 
potential application is with wavelets, which are used for signal and image processing in 
many different application areas. For example, in radiomics, features from wavelet-
transformed X-ray computed tomography (CT) images were among a set of image 
features used for prognostic prediction in HNSCC [299]. In this dissertation, data 
similarity was assessed based on binned expression levels. Future research could 
investigate the performance of the proposed similarity measure for comparing images and 
data in terms of wavelet features. 
Another potential application is in tissue imaging using quantum dots (QDs). QDs 
are fluorescent nanoparticles that can be conjugated to antibodies for targeted 
visualization of molecular and cellular targets [300, 301]. Compared to fluorescent dyes, 
QDs are advantageous because of their long-lasting fluorescence, target specificity, and 
multiplexing capabilities. Clinical applications are currently not possible due to the issue 
of heavy metal toxicity. However, this may change in the future as an initial trial in non-
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human primates showed no toxic effects during the first 90 days after administration 
[302]. However, QDs remain valuable for research applications. In recent HNSCC 
research in particular, QDs have been used to investigate the association of aldehyde 
dehydrogenease 1 with lymph node metastasis [303] and that of caveolin-1 with clinical 
stage, histological grade, and cancer development [304]. Additionally, QD-based 
immunohistofluorescence was observed to have greater sensitivity and objectivity 
compared to immunohistochemistry in an HNSCC application [303]. The multivariate 
hypergeometric similarity measure developed in Chapter 2 provides a framework for 
comparing fluorescent images, particularly when using multiplexed QDs. In one scenario, 
each bin (i.e., the class to which a pixel is assigned) in the reference and query images 
could represent a QD expression intensity level, enabling two QDs to be compared. In 
another scenario, each bin could represent an n-dimensional vector of expression levels 
for a group of n QDs, thereby enabling similarity assessment of multiplexed QD data.  
7.3.2. Design and Development of Novel Mathematical Models 
The design and development of new modeling techniques can assist in many 
biomedical research areas, including HNSCC. In the following section, I identify key 




Chapters 4 and 5 have demonstrated the development of integrated –omics 
models for predicting clinically relevant endpoints. However, all data currently used is 
static, obtained at a single time-point. Metabolomics data in particular is highly dynamic, 
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and has shown potential not only for early diagnosis but also for monitoring of disease 
status [160, 161, 305]. This reveals an opportunity to develop predictive models which 
utilize time-series –omic data to track patient risk and prognosis over time. Such models 
could help clinicians monitor the status of their patients and could serve to improve 
personalized medicine.   
 
Ensemble Model Construction 
Chapters 4 and 5 have also demonstrated how integrated ensemble modeling 
techniques can improve prediction performance. However, selecting the most appropriate 
ensemble from among all possible ensembles can be challenging, especially to users from 
non-computational backgrounds. A second predictive modeling layer could help to 
address this issue. For example, the input to such a model could be a new dataset of 
interest. Given historical performance patterns observed for other datasets across various 
models (as in Chapter 5), a similarity-based approach (as in Chapter 2) could be used to 
compare dataset properties, and thereby identify corresponding ensemble constructions 
that are likely to yield good performance on the new dataset.  
 
Systems Models 
Chapter 6 developed multi-scale models for predicting the response to natural 
compounds. While my previous HNSCC system model used parameters based on 
experimental data [245], parameter estimation was necessary for the more complex multi-
scale model. Thus, a key direction for improvement is parameterization of molecular- and 
cellular-level processes based on experimental measurements. This could be a dynamic 
154 
 
process in itself. For example, when a new cell line or patient becomes available, such a 
model could accept accompanying time-series data and automatically extract relevant 
parameters. If no data is available, a similarity-based approach (as in Chapter 2) may be 
used to identify the most relevant previously examined samples, and adapt experimental 
parameters from them. This would reduce the number of parameters to be estimated via 
error minimization. Next, another direction for improvement is to expand the list of 
processes associated with the multi-scale ABM to include movement and mechanical 
interactions. This would enable more realistic prediction of cellular-level behaviors, and 
investigation of cancer-relevant processes like invasion and metastasis. Lastly, 
nanoparticles – including gold nanoparticles – have been proposed as delivery vehicles to 
improve bioavailability of natural compounds [54, 306]. In addition, there has been 
evidence that the combination of natural compounds and hyperthermia can have 
synergistic effects [307]. Thus, the multi-scale ABM could be integrated with models for 
nanoparticle-based drug delivery and hyperthermia for cancer treatment, a subject which 
I have previously reviewed [308].    
7.3.3. Concluding Remarks 
In this dissertation, I have developed a suite of mathematical modeling tools to 
address key challenges in HNSCC research. It includes mathematical models for data 
mining and system dynamics that have been successfully applied to investigate HNSCC 
molecular characteristics, progression, and chemoprevention response. In the preceding 
sections, I have also discussed several potential seeds for future investigations, building 
upon this work. Overall, this dissertation contributes to the research space by accelerating 
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